(19) DANMARK

(10) DK/EP 3319643 T3

(12) Oversættelse af europæisk patentskrift

Patent- og Varemærkestyrelsen

(51) Int.Cl.: *A 61 K 51/04 (2006.01)* *A 61 P 35/00 (2006.01)* *C 07 B 59/00 (2006.01)*
*C 07 D 257/02 (2006.01)* *C 07 D 295/145 (2006.01)* *C 07 F 9/38 (2006.01)*
*C 07 F 9/6524 (2006.01)*

(45) Oversættelsen bekendtgjort den: **2020-06-15**

(80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2020-04-22**

(86) Europæisk ansøgning nr.: **16821892.3**

(86) Europæisk indleveringsdag: **2016-07-06**

(87) Den europæiske ansøgnings publiceringsdag: **2018-05-16**

(86) International ansøgning nr.: **US2016041040**

(87) Internationalt publikationsnr.: **WO2017007790**

(30) Prioritet: **2015-07-07 US 201562189652 P** **2016-04-08 US 201662320296 P**

(84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

(73) Patenthaver: **Five Eleven Pharma Inc., 3700 Market Street , Suite 305, Philadelphia, Pennsylvania 19104, USA**

(72) Opfinder: **KUNG, Hank F., 232 N Highland Road, Springfield, Pennsylvania 19064, USA**
**CHOI, Seok Rye, 52 Andrew Court, Aston, Pennsylvania 19014, USA**
**PLOESSL, Karl, 1525 Delaware Avenue 3, Wilmington, Delaware 19806, USA**
**WU, Zehui, Room 1306, Unit 2, Building 5, No. 16 Yuan, Guogongzhuang Middle Street, Fengtai District, Beijing, Kina**
**ZHA, Zhihao, 4119 Powelton Ave, Philadelphia, Pennsylvania 19104, USA**

(74) Fuldmægtig i Danmark: **Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S, Danmark**

(54) Benævnelse: **HBED-bisphosphonater og radiometalkonjugater deraf, anvendelige som theranostiske midler**

(56) Fremdragne publikationer:
**EP-A1- 2 862 857**
**US-A1- 2004 242 631**
**US-A1- 2012 148 492**
**US-A1- 2014 038 873**
**US-B2- 7 161 000**
**UEHAR ET AL.: 'Assessment of 186Re chelate-conjugated bisphosphonate for the development of new radiopharmaceuticals for bones' NUCLEAR MEDICINE AND BIOLOGY vol. 34, 2007, pages 79 - 87, XP005823969**

# DESCRIPTION

## BACKGROUND OF THE INVENTION

**[0001]** [$^{99m}$Tc]-methylene disphosphonate (MDP) planar or single-photon emission computerized tomography (SPECT) bone imaging is one of the most commonly performed nuclear medicine procedures to evaluate bone disorders, such as infection (osteomyelitis), noninfectious inflammation (arthritis), trauma, metabolic bone disease, benign and malignant neoplasms, and metastasis. Nevertheless, concerns are expressed about recurring shortages of $^{99m}$Tc, which may limit the availability of this imaging agent for routine clinical use. Recently, [$^{18}$F]NaF in conjunction with PET has been approved for the clinical evaluation of patients with known or suspected bone metastases. Iagaru A, et al., Clin. Nucl. Med. 38:e290-6 (2013); Jadvar H, et al., Semin. Nucl. Med. 45:58-65 (2015). There is currently an increasing number of regional commercial distribution centers for PET radiotracers, thus improving the availability of [$^{18}$F]NaF ($t_{1/2}$ 110 min, 97% $\beta^+$, 0.63 MeV max energy) for routine clinical practice.

**[0002]** $^{68}$Ge/$^{68}$Ga generators for PET imaging are becoming increasingly available in nuclear medicine clinics. Velikyan I., J. Label. Compd. Radiopharm. DOI: 10.1002/jlcr.3250 (published online February 17, 2015). There are several advantages associated with using $^{68}$Ga: 1) A long-lived parent isotope, germanium-68 ($^{68}$Ge) ($t_{1/2}$ 271 d), allows for an easy and widespread generator distribution; 2) The physical properties of $^{68}$Ga ($t_{1/2}$ 68 min, 89% $\beta^+$, 1.90 MeV max energy) are highly suitable for PET imaging; 3) $^{68}$Ge/$^{68}$Ga generators provide a convenient mechanism for position emitting isotope production without the need for a nearby cyclotron. An important factor to consider is that the emitting $\beta^+$ energy for $^{18}$F and $^{68}$Ga is 0.63 MeV and 1.90 MeV, respectively. However, despite the difference in the $\beta^+$ energy, $^{18}$F and $^{68}$Ga radiopharmaceuticals exhibit similar spatial resolution, sensitivity, image contrast, and activity recovery coefficients in human tissue, and they produce comparable clinical images in humans.

**[0003]** Due to the relatively short physical half-life of $^{68}$Ga and its potential for binding to the blood component transferrin, several essential properties for $^{68}$Ga radiopharmaceuticals are needed: 1) The $^{68}$Ga complexes should display high in vitro stability; 2) The formation of $^{68}$Ga complexes should be kinetically fast; 3) $^{68}$Ga complexes should be able to form bifunctional molecules for targeting, pre-conjugation, to biologically active molecules; and 4) $^{68}$Ga complexes should display suitable in vivo stability in blood circulation with minimal transferrin exchange.

**[0004]** Currently, the most common $^{68}$Ga labeled radiopharmaceuticals evaluated are

[$^{68}$Ga]DOTATOC, [$^{68}$Ga]DOTATATE, and [$^{68}$Ga]DOTANOC. These compounds are mainly used for detecting the over-expression of somatostatin receptors associated with neuroendocrine tumors. This has attracted significant attention for using PET imaging in the diagnosis of neuroendocrine tumor and various diseases. Morgat C. et al., Gallium-68: chemistry and radiolabeled peptides exploring different oncogenic pathways, Cancer Biother. Radiopharm. 28:85-97 (2013); Sandstrom M, et al. J. Nucl. Med. 54:1755-9 (2013); Velikyan I, et al., Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification, J. Nucl. Med. 55:204-10 (2014).

**[0005]** A number of Ga complexes have been reported, and they are usually macrocyclic or acyclic polyaza carboxylic acids. These complexes often include metal-chelating ligands designed to form gadolinium (Gd) complexes for use as magnetic resonance imaging (MRI) contrast agents, such as: diethylenetriaminepentaacetic acid (DTPA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), and related derivatives (Table 1). Many of these ligands are commonly employed to chelate radioactive metal ions. These include single photon emitting isotopes for SPECT imaging - $^{67}$Ga, $^{99m}$Tc, and $^{111}$In, as well as positron emitting isotopes for PET imaging - $^{64}$Cu, $^{86}$Y, $^{89}$Zr, $^{68}$Ga, and $^{89}$Sr. Literature reports on polyaza carboxylic acids such as DOTA and related ligands, suggest that they form highly thermodynamic stable complexes with Ga(III). Nevertheless, the complexation of no-carrier-added (n.c.a.) $^{68}$Ga with DOTA derivatives has been shown to be inefficient, often requiring heating of 80-100 °C. The formation of DOTA ligands with Ga(III) is more sensitive to experimental conditions than that of NOTA analogs. It is likely that the smaller cavity created by the NOTA derivatives fits tighter to the ionic radius of Ga(III). NOTA derivatives, especially 1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononane (NODAGA), were shown to be more suitable for chelating the Ga(III) ion than DOTA derivatives. Price E.W. and Orvig C., Chem. Soc. Rev. 43:260-90 (2014); Oxboel J., et al., Nucl. Med. Biol. 41:259-67 (2014). The Ga(III)NODAGA complexes exhibited much higher thermodynamic stability as well as rapid complex kinetics. As Ga(III) is a small ion and generally requires an octahedral coordination sphere, Ga(III)NODAGA analogs provide optimal in vitro and in vivo stability. There are several reports in which Ga(III)NODAGA was preferentially chosen as the chelating group in producing bifunctional imaging agents. By using DOTA and NOTA derivatives, many $^{68}$Ga labeled bisphosphonates were prepared and tested for bone imaging. It was reported that a bisphosphonate DOTA derivative, [$^{68}$Ga] 4-{[(bis-phosphonomethyl) carbomoyl]methyl}-7,10-bis-(carboxy-methyl)-1,4,7,10-tetraazacyclododec-1-yl)-acetic acid (BPAMD), displayed good bone uptake and retention in humans. Fellner M., et al., Eur. J. Nucl. Med. Mol. Imaging 37:834 (2010).

**[0006]** Table 1, depicts the structures of bisphosphonates that are reported to be capable of complexing $^{68}$Ga for bone imaging. These include ethylene-diamino-*N*,*N*,*N*',*N*'-tetrakismethylene-phosphoric acid (EDTMP), (4-{[(bis-phosphonomethyl)carbomoyl]methyl}-7,10-bis-(carboxy-methyl)-1,4,7,10-tetraazacyclododec-

1-yl)-acetic acid (BPAMD), (4-{[(bis-phosphonopropyl)carbomoyl]methyl}-7,10-bis-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl)-acetic acid (BPAPD), tetraethyl-10-{[(2,2-bis-phosphonoethyl)-hydroxyl phosphoryl]methyl}-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (BPPED or DO3ABP)), (4-{[(bis-phosphonopropyl)carbomoyl]hydroxylmethyl}-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA-BP), 2,2'-(7-(((2,2-diphosphonoethyl) (hydroxy)phosphoryl)methyl)-1,4,7-triazo-nane-1,4-diyl)diacetic acid (NO2APBP), 4-{[(bis-phosphonopropyl) carbomoyl]methyl}-1,4,7-triaza cyclonone-1,4-diacetic acid (NOTAMBP), 1,4,7-triazacyclononane-N,Nne-1,tris(bis-phosphonopropyl) carbomoyl]methyl-methylenephosphonic) acid (TRAP (NOTP)), and 1,4,7-triazacyclononane-1,4,7-tri[methylene phosphinic acid] (TRAP(MDP)$_3$). The DOTA and NOTA based bisphosphonates, $^{68}$Ga labeled BPAMD and NO2APBP, have been successfully tested in humans as bone-imaging agents.

**Table 1. Bisphosphonates that Can Complex $^{68}$Ga for Bone Imaging**




**[0007]** Several chelating groups reported for complexing Ga(III) are: DOTA, 1,4,7-triazacyclononane-1,4-bis[methylene(hydroxymethyl)phosphinic acid]-7-[methylene(2-carboxyethyl)phosphinic acid] (TRAP (NOPO)), cyclohexyl-1,2-[[6-carboxy-pyridin-2-yl]-methylamino]ethane ($H_2$CHX DEDPA), and (5*S*,8*S*,22*S*,26*S*)-1-amino-5,8-dibenzyl-4,7,10,19,24-pentaoxo-3,6,9,18,23,25-hexaazaoctacosane-22,26,28-tri-carboxylic acid trifluoroacetate (CHX-A"-DTPA-DUPA-Pep). *See* Simecek J., et al., Chem. Med. Chem. 8:95-103 (2013); Ramogida C.F., et al., Inorg. Chem. 54:2017-31 (2015); Baur B., et al., Pharmaceuticals (Basel) 7:517-29 (2014).

**[0008]** Prostate-specific membrane antigen (PSMA) is a highly specific prostate epithelial cell membrane antigen. Many reports suggest that PSMA is highly expressed in various tumors, including prostate cancer. Often, PSMA expression increases in higher-grade cancers and metastatic diseases. In a majority of neovasculature in solid tumors, there is high expression of PSMA, but not in normal vasculature. This makes PSMA a suitable target for cancer detection and therapy. Certain Ga-prostate specific membrane antigen (PSMA) tagged complexes showed high-affinity binding and effective targeting of PSMA-expressing tumor models in vitro. Two studied agents for imaging PSMA binding sites in cancer patients are [$^{68}$Ga]Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (monomer), and its related dimer, [$^{68}$Ga](Glu-NH-CO-NH-Lys(Ahx))$_2$-HBED-CC. Both complexes were prepared and were reported to show high PSMA binding as seen in Table 2. Baur B., et al., Pharmaceuticals (Basel) 7:517-29 (2014); Schafer M., et al., EJNMMI Res 2:23 (2012); Eder M., et al., Pharmaceuticals (Basel) 7:779-96 (2014); Eder M., et al., Bioconjug. Chem. 23:688-97 (2012). Although both [$^{68}$Ga]Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (monomer) and [$^{68}$Ga](Glu-NH-CO-NH-Lys(Ahx))$_2$-HBED-CC (dimer) exhibited comparable preclinical data, the current PSMA/PET imaging agent of choice for human study is the monomer. It is generally accepted that Glu-NH-CO-NH-Lys(Ahx)- provides high binding affinity to the PSMA receptors on the cell membrane of tumors.

**Table 2.**

| Proposed structures of PSMA targeting imaging agents [$^{68}$Ga]Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (monomer) and [$^{68}$Ga](Glu-NH-CO-NH-Lys(Ahx))$_2$-HBED-CC (dimer). | |
|---|---|
|  [$^{68}$Ga](Glu-NH-CO-NH-Lys(Ahx))-HBED-CC Monomer |  [$^{68}$Ga](Glu-NH-CO-NH-Lys(Ahx))$_2$-HBED-CC Dimer |

**[0009]** Most clinical studies to date have been performed with [$^{68}$Ga]Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (monomer). Using HBED instead of commonly employed DOTA and NOTA, as a ligand for chelating Ga(III) has certain advantages. Stability constants (log Kd) for Ga(III)-DOTA and Ga(III)-NOTA complexes were previously reported (log Kd = 21.3 and 31.0, respectively). Compared to DOTA and NOTA, the HBED chelating group forms a stronger, more stable Ga(III) complex: a log Kd value of 38.5 was reported for Ga(III)-HBED-CC.

**[0010]** A need continues to exist for bone imaging agents that employ available radionuclides, form complexes quickly, are stable in vitro and in vivo, and do not rapidly transfer radionuclide to transferrin in the bloodstream.

**BRIEF SUMMARY OF THE INVENTION**

**[0011]** One aspect of the invention is to novel bisphosphonate derivatives of HBEB CC and complexes thereof with metal radionuclides.

**[0012]** In one embodiment, the disclosure relates to a compound according to Formula I:



**Formula I**

or a pharmaceutically acceptable salt thereof, whe
rein

A is a divalent linking moiety comprising 1 to 10 carbon atoms in a chain, a ring, or a combination thereof, wherein at least one carbon atom is optionally replaced with O, -$NR^9$-, or -C(O)-;

B is $CR^3R^4$;

X is selected from the group consisting of:



;

n is from 1 to 8;

Y is independently CH or N;

$R^2$, $R^5$, and $R^8$ are independently hydrogen or a carboxylic acid protecting group;

$R^3$ and $R^4$ are independently hydrogen, a ($C_1$-$C_{10}$)alkyl group, an ethylene glycolyl group, or a propylene glycolyl group;

$R^6$ is hydrogen or a ($C_1$-$C_6$) acyl group; and

$R^7$ is the α-position substituent of a naturally occurring or non-naturally occurring amino acid, and

$R^9$ is independently selected from the group consisting of H, alkyl, cycloalkyl, heterocycloalkyl, aryl, alkylaryl, arylalkyl and heteroaryl.

**[0013]** In another embodiment, the disclosure relates to a complex between a compound of Formula I and a metal M, wherein M is selected from the group consisting of $^{44}Sc$, $^{47}Sc$, $^{203}Pb$, $^{67}Ga$, $^{68}Ga$, $^{72}As$, $^{111}In$, $^{90}Y$, $^{97}Ru$, $^{62}Cu$, $^{64}Cu$, $^{52}Fe$, $^{52m}Mn$, $^{140}La$, $^{175}Yb$, $^{153}Sm$, $^{166}Ho$, $^{149}Pm$, $^{177}Lu$, $^{142}Pr$, $^{159}Gd$, $^{213}Bi$, $^{67}Cu$, $^{111}Ag$, $^{199}Au$, $^{161}Tb$, and $^{51}Cr$.

**[0014]** In another embodiment, the disclosure relates to a compound according to Formula II:



**Formula II**

or a pharmaceutically acceptable salt thereof, whe
rein

A is a divalent linking moiety comprising 1 to 10 carbon atoms in a chain, a ring, or a combination thereof, wherein at least one carbon atom is optionally replaced with O, -$NR^9$-, or -C(O)-;

B is $CR^3R^4$;

X is selected from the group consisting of:



$X_1$ $X_2$ $X_3$ $X_4$ $X_5$ $X_6$ ;

where n is from 1 to 8;

Y is independently CH or N;

$R^1$ is hydrogen or a ($C_1$-$C_6$)alkyl group;

$R^3$ and $R^4$ are independently hydrogen, a ($C_1$-$C_{10}$)alkyl group, an ethylene glycolyl group, or a propylene glycolyl group;

$R^5$, and $R^8$ are independently hydrogen or a carboxylic acid protecting group;

$R^6$ is a ($C_1$-$C_6$) acyl group;

$R^7$ is the α-position substituent of a naturally occurring or non-naturally occurring amino acid;

$R^9$ is independently selected from the group consisting of H, alkyl, cycloalkyl, heterocycloalkyl, aryl, alkylaryl, arylalkyl and heteroaryl; and

M is a metal selected from the group consisting of $^{44}Sc$, $^{47}Sc$, $^{203}Pb$, $^{67}Ga$, $^{68}Ga$, $^{72}As$, $^{111}In$, $^{90}Y$, $^{97}Ru$, $^{62}Cu$, $^{64}Cu$, $^{52}Fe$, $^{52m}Mn$, $^{140}La$, $^{175}Yb$, $^{153}Sm$, $^{166}Ho$, $^{149}Pm$, $^{177}Lu$, $^{142}Pr$, $^{159}Gd$, $^{213}Bi$, $^{67}Cu$, $^{111}Ag$, $^{199}Au$, $^{161}Tb$, and $^{51}Cr$.

**[0015]** In another embodiment, the disclosure relates to a complex between a compound of Formula I, wherein X is X6, and a metal M. In one embodiment, M is $^{44}Sc$, $^{47}Sc$, $^{90}Y$, $^{97}Ru$, and $^{177}Lu$; the remaining groups are as defined for Formula I, wherein the radio metal is complexed at the X6 (DOTA) moiety.

**[0016]** Another embodiment of the present disclosure relates to methods of forming a radiolabeled complex of a compound of Formula I.

**[0017]** Another embodiment of the present disclosure relates to a method of detecting by administering to a subject a radiolabeled complex of a compound of Formula I or administering to a subject a complex of Formula II, and thereafter imaging said subject or a portion of said subject.

**[0018]** Another embodiment of the present disclosure relates to the complexes of the invention for use in methods of treating bone tumors in a subject, said method comprising administering a radiolabeled complex of a compound of Formula I to said subject, wherein M is $^{44}Sc$, $^{47}Sc$, $^{90}Y$, $^{97}Ru$, and $^{177}Lu$.

**BRIEF DESCRIPTION OF THE FIGURES**

**[0019]**

FIG. 1 depicts sagittal, transaxial and coronal sections of microPET images of a normal mouse at 60 min post iv injection of [$^{18}$F]NaF.

FIG. 2 depicts sagittal, transaxial and coronal sections of microPET images of a normal mouse at 60 min post iv injection of [$^{68}$Ga]BPAMD.

FIG. 3 depicts sagittal, transaxial and coronal sections of microPET images of a normal mouse at 60 min post iv injection of [$^{68}$Ga]**1a**.

FIG. 4 depicts a graph that plots the time course of [$^{68}$Ga]1**g** uptakes into PSMA expressing LNCaP cells (% uptake/well).

FIG. 5 depicts cell uptakes of [$^{68}$Ga]**1g** after 1hr incubation at 37°C (% uptake/well). The PSMA positive LNCaP cells displayed excellent uptake while the PSMA negative PC3 cells exhibited no uptake. Specific PSMA inhibitor, 2-PMPA (2-(phosphonomethyl)pentane-1,5-dioic acid), blocked the cell uptake to PSMA positive LNCaP cells. (T: Total uptake, B: Blocking by 2-PMPA).

FIGs. 6A-6F depicts MicroPET images of mouse after injection of [$^{68}$Ga]**1g** (500 µCi, 60 min post injection, 15 min scan).

## DETAILED DESCRIPTION OF THE INVENTION

**[0020]** Positron emission tomography (PET) imaging using radio labeled bisphosphonates, for example $^{68}$Ga, to target bone metastasis can be a valuable tool for cancer diagnosis and for monitoring therapeutic treatment. A series of $^{68}$Ga labeled *N,N'*-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-*N,N'*-diacetic acid (HBED-CC) compounds containing one bisphosphonate group (**1a**) or two bisphosphonate groups (**2** and **3**), were prepared (Table 3). Additional bisphosphonate-HBED-CC containing compounds including conjugated 2-glucosamine (**1b**), glycine (**1c**), alanine (**1d**), aspartic acid (**1e**), glutamic acid (**1f**), Glu-NH-CO-NH-Lys(Ahx) (**1g**) and DOTA (**1h**) were also prepared. The new HBED ligands, **1a-h, 2**, and **3,** reacted rapidly in a sodium acetate buffer with [$^{68}$Ga]$GaCl_3$ eluted from a commercially available $^{68}$Ge/$^{68}$Ga generator (pH 4, >95% labeling at room temperature in 5 min) to form [$^{68}$Ga]**1a-h**, [$^{68}$Ga]**2**, and [$^{68}$Ga]**3**, respectively. This labeling condition avoids the need for further purification. The biodistribution of [$^{68}$Ga]**1a-h** and [$^{68}$Ga]**2** in normal mice after an i.v. injection showed excellent bone uptake and retention comparable to that of [$^{18}$F]NaF. However,

[$^{68}$Ga]**3** displayed high liver uptake and less bone localization, therefore it was not studied any further. The results suggest that [$^{68}$Ga]**1a-h** and [$^{68}$Ga]**2** are suitable as bone imaging agents in humans, serving as alternatives to the current bone imaging agent of choice, [$^{18}$F]NaF. Compounds of the invention provide practical in vivo bone imaging agents in conjunction with PET without the need of a near-by cyclotron.

**[0021]** Disclosed are a group of HBED-CC compounds containing bisphosphonates [68Ga]1a-h, [68Ga]2 and [68Ga]3 were prepared and tested. This series of new compounds, therefore, contains two independent components. First, the HBED chelating group forms a stable complex with 68Ga(III); second, the bisphosphonate group attached at the end of the chelating group is utilized for targeting and binding to hydroxyapatites on active bone surfaces, similar to the phosphonate group of [99mTc]MDP.

**Table 3**

Chemical structures of $^{68}$Ga labeled HBED-CC derivatives containing bisphosphonates, [$^{68}$Ga]**1a-h**, [$^{68}$Ga]**2**, and [$^{68}$Ga]**3**, and a known bone imaging agent, [$^{68}$Ga]BPAMD















Chemical structures of $^{68}$Ga labeled HBED-CC derivatives containing bisphosphonates, [$^{68}$Ga]**1a-h**, [$^{68}$Ga]**2**, and [$^{68}$Ga]**3**, and a known bone imaging agent, [$^{68}$Ga]BPAMD




**[0022]** In one embodiment, the disclosure relates to a compound according to Formula I:



**Formula I**

or a pharmaceutically acceptable salt thereof,
wherein

A is a divalent linking moiety comprising 1 to 10 carbon atoms in a chain, a ring, or a combination thereof, wherein at least one carbon atom is optionally replaced with O, -NR$^9$-, or -C(O)-;

B is $CR^3R^4$;

X is selected from the group consisting of:




;

n is from 1 to 8;

Y is independently CH or N;

$R^1$ is hydrogen or a ($C_1$-$C_6$) alkyl group;

$R^2$, $R^5$, and $R^8$ are independently hydrogen or a carboxylic acid protecting group;

$R^3$ and $R^4$ are independently hydrogen, a ($C_1$-$C_{10}$) alkyl group, an ethylene glycolyl group, or a propylene glycolyl group;

$R^6$ is hydrogen or a ($C_1$-$C_6$) acyl group; and

$R^7$ is the α-position substituent of a naturally occurring or non-naturally occurring amino acid, and

$R^9$ is independently selected from the group consisting of H, alkyl, cycloalkyl, heterocycloalkyl, aryl, alkylaryl, arylalkyl and heteroaryl. In one embodiment $R^9$ is H, alkyl, cycloalkyl, heterocycloalkyl, aryl, alkyl aryl and heteroaryl. In another embodiment, $R^9$ is H, alkyl or arylalkyl.

**[0023]** In one aspect, X is one of $X_1$, $X_2$, $X_3$, $X_4$ or $X_5$.

**[0024]** In another aspect, X is $X_6$. In one aspect, n is 1.

**[0025]** In another embodiment, the disclosure relates to a complex between a compound of Formula I and a metal M, wherein M is selected from the group consisting of $^{44}Sc$, $^{47}Sc$, $^{203}Pb$, $^{67}Ga$, $^{68}Ga$, $^{72}As$, $^{111}In$, $^{90}Y$, $^{97}Ru$, $^{62}Cu$, $^{64}Cu$, $^{52}Fe$, $^{52m}Mn$, $^{140}La$, $^{175}Yb$, $^{153}Sm$, $^{166}Ho$, $^{149}Pm$, $^{177}Lu$, $^{142}Pr$, $^{159}Gd$, $^{213}Bi$, $^{67}Cu$, $^{111}Ag$, $^{199}Au$, $^{161}Tb$, and $^{51}Cr$.

**[0026]** In another embodiment, the disclosure relates to a compound according to Formula II:



**Formula II**

or a pharmaceutically acceptable salt thereof,
wherein

A is a divalent linking moiety comprising 1 to 10 carbon atoms in a chain, a ring, or a combination thereof, wherein at least one carbon atom is optionally replaced with O, -$NR^9$-, or -C(O)-;

B is $CR^3R^4$;

X is selected from the group consisting of:





Y is independently CH or N;

n is from 1 to 8;

$R^1$ is hydrogen or a ($C_1$-$C_6$) alkyl group;

$R^3$ and $R^4$ are independently hydrogen, a ($C_1$-$C_{10}$) alkyl group, an ethylene glycolyl group, or a propylene glycolyl group;

$R^5$, and $R^8$ are independently hydrogen or a carboxylic acid protecting group;

$R^6$ is a ($C_1$-$C_6$) acyl group;

$R^7$ is the α-position substituent of a naturally occurring or non-naturally occurring amino acid;

$R^9$ is independently selected from the group consisting of H, alkyl, cycloalkyl, heterocycloalkyl, aryl, alkylaryl, and heteroaryl; and

M is a metal selected from the group consisting of $^{44}Sc$, $^{47}Sc$, $^{203}Pb$, $^{67}Ga$, $^{68}Ga$, $^{72}As$, $^{111}In$, $^{90}Y$, $^{97}Ru$, $^{62}Cu$, $^{64}Cu$, $^{52}Fe$, $^{52m}Mn$, $^{140}La$, $^{175}Yb$, $^{153}Sm$ , $^{166}Ho$, $^{149}Pm$, $^{177}Lu$, $^{142}Pr$, $^{159}Gd$, $^{213}Bi$, $^{67}Cu$, $^{111}Ag$, $^{199}Au$, $^{161}Tb$, and $^{51}Cr$.

**[0027]** In one aspect, M is $^{67}Ga$ or $^{68}Ga$.

**[0028]** In certain embodiments, the compounds of the present invention are represented by generalized Formula I and II and the attendant definitions, wherein A is a divalent linking moiety comprising 1 to 10 carbon atoms in a chain, a ring, or a combination thereof, wherein at least one carbon atom is optionally replaced with O, -$NR^9$-, or -C(O)-. In another embodiment, A is a divalent linking moiety comprising a $C_1$-$C_{10}$ alkylene group wherein at least one carbon atom is optionally replaced with O, -$NR^9$-, or -C(O)-. In another embodiment, A is $(CH_2)_m$, wherein m is an integer from 0 to 6. In another embodiment, A is $CH_2$. Useful examples of the

divalent A moiety include $-CH_2-$, $-CH_2CH_2-$, $-CH_2CH_2CH_2-$, $-OCH_2-$, $-OCH_2CH_2-$, $-OCH_2CH_2CH_2-$, $-NHCH_2-$, $-NHCH_2CH_2-$, $-NHCH_2CH_2CH_2-$,$-COCH_2-$, $-COCH_2CH_2-$, and $-COCH_2CH_2CH_2-$.

**[0029]** In certain embodiments, the compounds of the present invention are represented by generalized Formula I and II and the attendant definitions, wherein X is selected from the group consisting of:



$X_1$ $X_2$ $X_3$ $X_4$ $X_5$ $X_6$

**[0030]** In other embodiments, X of Formula I or Formula II is:



$X_6$

**[0031]** In some embodiments, X of Formula I or Formula II is X6 and n is 1.

**[0032]** In another embodiment, X is a carboxylic acid group or its derivative (X1). In another embodiment, X contains glucosamine group or its derivative (X2). In another embodiment, X contains an amino acid residue or its derivative (X3). In another embodiment, X contains Glu-NH-CO-NH-Lys(Ahx) (X4). In another embodiment, X contains a bisphosphonate group (X5).

**[0033]** Useful $R^7$ groups include glycine, aspartic acid, glutamic acid, and 2-glucosamine.

**[0034]** Useful $R^5$ and $R^8$ groups include a methyl ester, a t-butyl ester, a benzyl ester, and an allyl ester.

**[0035]** In one embodiment, X is one of $X_1$ to $X_5$ and the radionuclide metal (M) is $^{68}Ga$. In another embodiment, X is $X_6$ and the radio metal is $^{177}Lu$ or $^{90}Y$.

**[0036]** In one embodiment, the disclosure relates to a compound having the structure:



wherein n is from 1 to 8. In one embodiment, n is 1.

**[0037]** In one embodiment, the disclosure relates to a compound having the structure:



wherein n is from 1 to 8. In one embodiment, n is 1.

**[0038]** The present invention also provides pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound or a pharmaceutically acceptable salt of Formula I or Formula II. In certain embodiments the pharmaceutical composition will comprise the reaction precursors necessary generate the compound or salt according to Formula I or subformula thereof upon combination with a radiolabeled precursor.

**[0039]** The present invention provides a kit formulation, comprising a sterile container containing a compound of Formula I or a pharmaceutically acceptable isotonic solution for iv injection thereof, and instructions for diagnostic imaging ($^{68}$Ga) and radiation therapy use ($^{177}$Lu and $^{90}$Y).

**[0040]** The present invention also provides for methods of in vivo imaging, comprising administering an effective amount of a radiometal complex of Formula II to a subject, and detecting the pattern of radioactivity of the complex in said subject.

**[0041]** Typical subjects to which compounds of the invention may be administered will be mammals, particularly primates, especially humans. For veterinary applications, a wide variety of subjects will be suitable, e.g. livestock such as cattle, sheep, goats, cows, swine and the like; poultry such as chickens, ducks, geese, turkeys, and the like; and domesticated animals particularly pets such as dogs and cats. For diagnostic or research applications, a wide variety of mammals will be suitable subjects including rodents (e.g. mice, rats, hamsters), rabbits, primates, and swine such as inbred pigs and the like. Additionally, for in vitro applications, such as in vitro diagnostic and research applications, body fluids and cell samples of the above subjects will be suitable for use such as mammalian, particularly primate such as human, blood, urine or tissue samples, or blood urine or tissue samples of the animals mentioned for

veterinary applications.

**[0042]** One useful radiopharmaceutical in accordance with this invention are positron emitting gallium-68 complexes which, when used in conjunction with a $^{68}Ge/^{68}Ga$ parent/daughter radionuclide generator system, will allow PET imaging studies, avoiding the expense associated with operation of an in-house cyclotron for radionuclide production.

**[0043]** The radiopharmaceutical complexes are used in accordance with the present method for bone imaging. The complexes are formulated into aqueous solutions suitable for intravenous administration using standard techniques for preparation of parenteral diagnostics. An aqueous solution of the present complexes can be sterilized, for example, by passage through a commercially available 0.2 micron filter. The complexes are typically administered intravenously in an amount effective to provide bone concentrations of the radionuclide complex sufficient to provide the requisite photon (gamma/positron) flux for imaging the tissue. The dosage level for any given complex of this invention to achieve acceptable tissue imaging depends on its particular biodistribution and the sensitivity of the tissue imaging equipment. Effective dosage levels can be ascertained by routine experimentation. They typically range from about 1 to about 30 millicuries. Where the complexes are gallium-68 complexes for PET imaging of bone, adequate photon fluxes can be obtained by intravenous administration of from about 1 to about 30 millicuries of the complex.

**[0044]** The term "amino acid" used herein include both naturally occurring amino acids and unnatural amino acids. Naturally occurring amino acid refers to amino acids that are known to be used for forming the basic constituents of proteins, including alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamine, glutamic acid, glycine, histidine, hydroxyproline, isoleucine, leucine, lysine, methionine, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and combinations thereof. Examples of unnatural amino acids include: an unnatural analogue of a tyrosine amino acid; an unnatural analogue of a glutamine amino acid; an unnatural analogue of a phenylalanine amino acid; an unnatural analogue of a serine amino acid; an unnatural analogue of a threonine amino acid; an alkyl, aryl, acyl, azido, cyano, halo, hydrazine, hydrazide, hydroxyl, alkenyl, alkynl, ether, thiol, sulfonyl, seleno, ester, thioacid, borate, boronate, phospho, phosphono, phosphine, heterocyclic, enone, imine, aldehyde, hydroxylamine, keto, or amino substituted amino acid, or any combination thereof; an amino acid with a photoactivatable cross-linker; a spin-labeled amino acid; a fluorescent amino acid; an amino acid with a novel functional group; an amino acid that covalently or noncovalently interacts with another molecule; a metal binding amino acid; a metal-containing amino acid; a radioactive amino acid; a photocaged and/or photoisomerizable amino acid; a biotin or biotin-analogue containing amino acid; a glycosylated or carbohydrate modified amino acid; a keto containing amino acid; amino acids comprising polyethylene glycol or polyether; a heavy atom substituted amino acid; a chemically cleavable or photocleavable amino acid; an amino acid with an elongated side chain; an amino acid containing a toxic group; a sugar substituted amino acid, e.g., a sugar substituted serine or the like; a carbon-linked sugar-containing amino acid; a redox-active amino acid; an α-hydroxy containing acid; an amino thio acid containing amino acid; an α,α disubstituted amino acid; a β-amino acid; and a cyclic amino

acid other than proline.

**[0045]** The term "acyl" used herein refers to the following structure:



,

wherein $R^{20}$ is alkyl, cycloalkyl, aryl, (cycloalkyl)alkyl, or arylalkyl, any of which is optionally substituted. The acyl group can be, for example, $C_{1-6}$ alkylcarbonyl (such as, for example, acetyl), arylcarbonyl (such as, for example, benzoyl), levulinoyl, or pivaloyl. In another embodiment, the acyl group is benzoyl.

**[0046]** The term "alkyl" used herein includes both branched and straight-chain saturated aliphatic hydrocarbon groups, having the specified number of carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s-pentyl. Preferred alkyl groups are $C_1$-$C_{10}$ alkyl groups. Typical $C_{1-10}$ alkyl groups include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, and n-decyl, isopropyl, *sec*-butyl, *tert*-butyl, *iso*-butyl, *iso*-pentyl, neopentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 3-ethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-methylhexyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 1,2-dimethylpentyl, 1,3-dimethylpentyl, 1,2-dimethylhexyl, 1,3-dimethylhexyl, 3,3-dimethylhexyl, 1,2-dimethylheptyl, 1,3-dimethylheptyl, and 3,3-dimethylheptyl, among others. In one embodiment, useful alkyl groups are selected from straight chain $C_{1-6}$ alkyl groups and branched chain $C_{3-6}$ alkyl groups. Typical $C_{1-6}$ alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, *sec*-butyl, *tert*-butyl, *iso*-butyl, pentyl, 3-pentyl, hexyl, among others. In one embodiment, useful alkyl groups are selected from straight chain $C_{2-6}$ alkyl groups and branched chain $C_{3-6}$ alkyl groups. Typical $C_{2-6}$ alkyl groups include ethyl, propyl, isopropyl, butyl, *sec*-butyl, *tert*-butyl, *iso*-butyl, pentyl, 3-pentyl, hexyl among others. In one embodiment, useful alkyl groups are selected from straight chain $C_{1-4}$ alkyl groups and branched chain $C_{3-4}$ alkyl groups. Typical $C_{1-4}$ alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, *sec*-butyl, *tert*-butyl, and *iso*-butyl.

**[0047]** The term "cycloalkyl" used herein includes saturated ring groups, having the specified number of carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. Cycloalkyl groups typically will have 3 to about 12 ring members. In one embodiment, the cycloalkyl has one or two rings. In another embodiment, the cycloalkyl is a $C_3$-$C_8$ cycloalkyl. In another embodiment, the cycloalkyl is a $C_{3-7}$ cycloalkyl. In another embodiment, the cycloalkyl is a $C_{3-6}$ cycloalkyl. Exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, decalin, and adamantyl.

**[0048]** The term "heterocycloalkyl" used herein refers to saturated heterocyclic alkyl groups.

**[0049]** The term "aryl" used herein includes $C_{6-14}$ aryl, especially $C_{6-10}$ aryl. Typical $C_{6-14}$ aryl groups include phenyl, naphthyl, phenanthryl, anthracyl, indenyl, azulenyl, biphenyl, biphenylenyl, and fluorenyl groups, more preferably phenyl, naphthyl, and biphenyl groups.

**[0050]** The term "heteroaryl" or "heteroaromatic" used herein refers to groups having 5 to 14 ring atoms, with 6, 10 or 14 π electrons shared in a cyclic array, and containing carbon atoms and 1, 2, or 3 oxygen, nitrogen or sulfur heteroatoms, or 4 nitrogen atoms. In one embodiment, the heteroaryl group is a 5- to 10-membered heteroaryl group. Examples of heteroaryl groups include thienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl, benzofuryl, pyranyl, isobenzofuranyl, benzooxazonyl, chromenyl, xanthenyl, 2*H*-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, 3*H*-indolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, cinnolinyl, quinazolinyl, pteridinyl, 4a*H*-carbazolyl, carbazolyl, β-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, thiazolyl, isothiazolyl, phenothiazolyl, isoxazolyl, furazanyl, and phenoxazinyl. Typical heteroaryl groups include thienyl (e.g., thien-2-yl and thien-3-yl), furyl (e.g., 2-furyl and 3-furyl), pyrrolyl (e.g., pyrrol-1-yl, 1H-pyrrol-2-yl and 1H-pyrrol-3-yl), imidazolyl (e.g., imidazol-1-yl, 1H-imidazol-2-yl and 1H-imidazol-4-yl), tetrazolyl (e.g., tetrazol-1-yl and tetrazol-5-yl), pyrazolyl (e.g., 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, and 1H-pyrazol-5-yl), pyridyl (e.g., pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl), pyrimidinyl (e.g., pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, and pyrimidin-5-yl), thiazolyl (e.g., thiazol-2-yl, thiazol-4-yl, and thiazol-5-yl), isothiazolyl (e.g., isothiazol-3-yl, isothiazol-4-yl, and isothiazol-5-yl), oxazolyl (e.g., oxazol-2-yl, oxazol-4-yl, and oxazol-5-yl) and isoxazolyl (e.g., isoxazol-3-yl, isoxazol-4-yl, and isoxazol-5-yl). A 5-membered heteroaryl can contain up to 4 heteroatoms. A 6-membered heteroaryl can contain up to 3 heteroatoms. Each heteroatom is independently selected from nitrogen, oxygen and sulfur.

**[0051]** Suitable carboxylic acid protecting group are well known and include, for example, any suitable carboxylic acid protecting group disclosed in Wuts, P. G. M. & Greene, T. W., Greene's Protective Groups in Organic Synthesis, 4rd Ed., pp. 16-430 (J. Wiley & Sons, 2007). Those skilled in the art will be familiar with the selection, attachment, and cleavage of protecting groups and will appreciate that many different protective groups are known in the art, the suitability of one protective group or another being dependent on the particular synthetic scheme planned. Suitable carboxylic acid protecting group include, for example, the methyl esters, t-butyl esters, benzyl esters, and allyl esters.

**Materials and Methods**

**General**

**[0052]** All reagents and solvents were purchased commercially (Aldrich, Acros, or Alfa Inc.) and were used without further purification, unless otherwise indicated. Solvents were dried

through a molecular sieve system (Pure Solve Solvent Purification System; Innovative Technology, Inc.). $^{1}H$ and $^{13}C$ NMR spectra were recorded on a Bruker Avance spectrometer at 400 MHz and 100 MHz, respectively, and referenced to NMR solvents as indicated. Chemical shifts are reported in ppm (δ), with a coupling constant, *J*, in Hz. The multiplicity is defined by singlet (s), doublet (d), triplet (t), broad (br), and multiplet (m). High-resolution mass spectrometry (HRMS) data was obtained with an Agilent (Santa Clara, CA) G3250AA LC/MSD TOF system. Thin-layer chromatography (TLC) analyses were performed using Merck (Darmstadt, Germany) silica gel 60 $F_{254}$ plates. Generally, crude compounds were purified by flash column chromatography (FC) packed with silica gel (Aldrich). High performance liquid chromatography (HPLC) was performed on an Agilent 1100 series system. A gamma counter (Cobra II auto-gamma counter, Perkin-Elmer) measured $^{68}Ga$ radioactivity. An aqueous solution of $[^{68}Ga]GaCl_3$ was obtained from a $^{68}Ge/^{68}Ga$ generator (iTG, Germany). Solid-phase extraction cartridges (SEP Pak® Light QMA, Oasis® HLB 3cc) were obtained from Waters (Milford, MA, USA). $[^{18}F]NaF$ was purchased from IBA (Somerset, NJ).

Scheme 1. **Synthesis of Compounds 1a-h**






**Example 1a-h**

**Preparation of Ligand**

**1. Dimethyl 3,3'-(((2,2,13,13-tetramethyl-4,11-dioxo-3,12-dioxa-6,9-diazatetradecane-6,9-diyl)bis(methylene))bis(4-hydroxy-3,1-phenylene))dipropanoate (4)**

**[0053]** As summarized in Scheme 1, di-*tert*-butyl 2,2'-(ethane-1,2-diylbis(azanediyl))diacetate (2 g, 6.94 mmol) and methyl 3-(4-hydroxyphenyl)propanoate (2.63 g, 14.5 mmol) were dissolved in ethanol (50 mL) and toluene (50 mL) in a 100 mL round-bottomed flask. Paraformaldehyde (4.3 g, 145 mmol) was added portion-wise with stirring, and the suspension was heated to reflux overnight. The solvent was then removed. The crude product was washed with water, extracted with dichloromethane (DCM), dried, filtered, evaporated, and purified by FC, to yield **4** as a colorless oil product (3.94 g, 84.5%, (EtOAc/hexane = 3/7). $^1$HNMR (400 MHz, $CDCl_3$) δ: 7.00 (dd, 2H, *J* = 2.0 Hz, *J* = 8.4 Hz), 6.77 (d, 2H, *J* = 8.4 Hz), 6.74 (d, 2H, *J* = 2.0 Hz), 3.70 (s, 4H), 3.67 (s, 6H), 3.17 (s, 4H), 2.83 (t, 4H, *J* = 7.8 Hz), 2.69 (s, 4H), 2.57 (t, 4H, *J* = 7.8 Hz), 1.46 (s, 18H). HRMS calcd for $C_{36}H_{53}N_2O_{10}$ 672.3700; found, 673.3680 $[M+H]^+$.

**2. 3,3'(((2,2,13,13-tetramethyl-4,11-dioxo-3,12-dioxa-6,9-diazatetradecane-6,9-diyl)bis(methylene))bis(4-hydroxy-3,1-phenylene))dipropanoic acid (5)**

**[0054]** To a stirred solution of **4** (1 g, 1.48 mmol) in methanol (20 mL) and $H_2O$ (20 mL), NaOH (5 mmol, 0.2 g) was added. The reaction continued to stir at room temperature overnight, and was neutralized by 1N HCl until pH = 7. Most of the solvent was then removed under vacuum, extracted with ethyl acetate, and dried over $MgSO_4$. The crude product was purified by FC

(dichloromethane/methanol$NH_4OH$, 90/9/1, V/V/V) to yield **5** as a white foam (909 mg, 94.7%). $^1H$ NMR (400 MHz, $CD_3OD$) δ: 7.05 (dd, *J* = 2.4, 2.0 Hz, 2H), 6.93 (d, *J* = 2.0 Hz, 2H), 6.72 (d, *J* = 8.4 Hz, 2H), 3.80 (s, 4H), 3.34-3.32 (m, 7H), 2.85-2.80 (m, 8H), 2.54-2.50 (m, 4H), 1.489 (s, 18H). $^{13}C$ NMR (100 MHz, $CD_3OD$) δ: 176.42, 170.14, 132.02, 130.05, 128.91, 121.21, 115.39, 81.80, 55.34, 54.67, 49.78, 36.49, 30.11, 26.98. HRMS calcd for $C_{34}H_{48}N_2O_{10}$ 644.3309; found, 645.3483 $[M+H]^+$.

**General synthetic procedures for 6a-h**

**[0055]** To a stirred solution of **5** (200 mg, 0.31 mmol) and one of the protected amino acids or protected glucose amines (0.31 mmol) in dimethylformamide (DMF) (20 mL), N,N-diisopropylethylamine (1 mL), N-hydroxybenzotriazole hydrate (HOBt) (84 mg, 0.62 mmol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) (118 mg, 0.62 mmol) were added sequentially. The mixture was stirred at room temperature for 3 h before tetraethyl aminomethylenediphosphonate (94 mg, 0.31 mmol) and HBTU (118 mg, 0.62 mmol) were added sequentially. The mixture was then stirred at room temperature overnight, diluted with EtOAc (50 mL), washed with brine (2 × 20 mL), dried over $Na_2SO_4$, concentrated, and purified by FC (DCM/MeOH = 10/1) to yield the desired product.

**6a:** To a stirred solution of **5** (100 mg, 0.15 mmol) and tetraethyl aminomethylenediphosphonate (52 mg, 0.17 mmol) in DMF (20 mL), triethyl amine (1 mL), HOBt (20 mg, 0.15 mmol), and EDCI (59 mg, 0.31 mmol) were added sequentially. The mixture was diluted with EtOAc (50 mL), washed with brine (2 × 25 mL), dried over $Na_2SO_4$, concentrated, and purified by FC (DCM/MeOH/$NH_4OH$ = 90/9/1) to yield **6a** as a white foam (63 mg, 44.3%). $^1$HNMR (400 MHz, $CDCl_3$) δ: 7.11-7.06 (m, 1H), 7.03-7.00 (m, 1H), 6.80-6.72 (m, 4H), 4.26-4.20 (m, 8H), 3.52-3.50 (m, 4H), 3.34 (s, 1H), 2.91-2.78 (m, 6H), 2.68-2.66 (m, 4H), 2.63-2.56 (m, 6H), 1.46 (s, 18H), 1.36 (t, *J* = 6.4 Hz, 12H). HRMS calcd for $C_{43}H_{69}N_3O_{15}P_2$ 929.4204; found 930.4209 $[M+H]^+$.

**6b:** Following the general procedure, treatment of **5** (200 mg, 0.31 mmol) with 1,3,4,6-tetra-*O*-acetyl-2-amino-2-deoxy-glucopyranose hydrochloride (118 mg, 0.31 mmol) afforded **6b** (111 mg, 28.4%) as a colorless oil. $^1H$ NMR (400 MHz, $CDCl_3$) δ: 9.50 (s, 1H), 7.01-6.97 (m, 2H), 6.79-6.66 (m, 5H), 5.34-5.24 (m, 1H), 5.14-4.98 (m, 1H), 4.14-4.09 (m, 8H), 3.69-3.59 (m, 6H), 3.20-3.18 (m, 4H), 2.87-2.47 (m, 8H), 2.67-2.53 (m, 6H), 2.41-2.37 (m, 2H), 1.45 (s, 18H), 1.35-1.30 (m, 12H), 1.27-1.23 (m, 12H). $^{13}C$ NMR (100 MHz, $CDCl_3$) δ: 172.66, 171.09, 170.89, 170.68, 170.20, 169.46, 169.24, 155.72, 155.61, 131.20, 130.99, 129.15, 129.04, 128.79, 121.60, 116.27, 92.46, 82.14, 82.09, 72.67, 2.43, 68.11, 63.81, 63.46, 61.74, 60.34, 57.58, 56.08, 55.87, 55.43, 52.77, 50.02, 38.42, 37.82, 30.69, 30.06, 28.03, 20.81, 20.68, 20.54, 16.32, 16.28, 14.16. HRMS calcd for $C_{57}H_{88}N_4O_{23}P_2$ 1258.5315, found: 1259.5321 $[M + H]^+$.

**6c:** Following the general procedure, treatment of **5** (200 mg, 0.31 mmol) with *tert*-Butyl aminoacetate hydrochloride (52 mg, 0.31 mmol) afforded **6c** (100 mg, 31.1%) as a colorless oil. $^{1}$H NMR (400 MHz, $CDCl_3$) δ: 9.53(s, 2H), 7.05-7.00 (m, 2H), 6.77-6.74 (m, 4H), 4.24-4.10 (m, 8H), 3.70-3.67 (m, 3H), 3.19- 3.16 (m, 6H), 2.95- 2.88 (m, 6H), 2.69-2.64 (m, 4H), 2.57-2.47 (m, 4H), 1.46 (s, 27H), 1.35-1.20 (m, 12H). $^{13}$C NMR (100 MHz, $CDCl_3$) δ: 172.35, 170.05, 155.82, 155.71, 131.38, 130.97, 129.15, 128.88, 121.56, 117.04, 116.39, 82.09, 63.66, 57.81, 55.70, 50.22, 42.01, 40.58, 38.40, 38.02, 30.48, 28.05, 16.33. HRMS calcd for $C_{49}H_{80}N_4O_{16}P_2$ 1042.5045, found: 1043.6564 $[M + H]^+$.

**6d:** Following the general procedure, treatment of **5** (200 mg, 0.31 mmol) with *L*-alanine tert-butyl ester hydrochloride (56 mg, 0.31 mmol) afforded **6d** (103 mg, 31.7%) as a colorless oil. $^{1}$H NMR (400 MHz, $CDCl_3$) δ: 7.03-6.97 (m, 2H), 6.84-6.76 (m 4H), 4.21-4.09 (m, 8H), 3.70 (s, 4H), 3.46 (s, 1H), 3.21 (s, 4H), 2.87-2.81 (m, 6H), 2.72-2.61 (m, 4H), 2.49-2.46 (m, 4H), 1.46 (s, 27H), 1.31-1.23 (m, 15H). $^{13}$C NMR (100 MHz, $CDCl_3$) δ: 172.39, 171.85, 170.17, 155.57, 131.41, 131.07, 129.40, 128.98, 121.50, 116.31, 115.44, 82.14, 64.03, 63.82, 63.57, 57,78, 55.65, 50.29, 48.59, 38.55, 37.77, 30.48, 28.03, 27.95. HRMS calcd for $C_{50}H_{82}N_4O_{16}P_2$ 1056.5201, found: 1057.7004 $[M + H]^+$.

**6e:** Following the general procedure, treatment of **5** (200 mg, 0.31 mmol) with *L*-aspartic acid di-tert-butyl ester hydrochloride (87 mg, 0.31 mmol) afforded **6e** (110 mg, 30.8%) as a colorless oil. $^{1}$H NMR (400 MHz, $CDCl_3$) δ: 7.03-6.98 (m, 2H), 6.80-6.73 (m, 4H), 5.11-4.98 (m, 1H), 4.20-4.08 (m, 8H), 3.71-3.66 (m, 6H), 3.46 (s, 1H), 3.16 (s, 4H), 2.96-2.83 (m, 6H), 2.70-2.65 (m, 6H), 2.58-2.55 (m, 1H), 2.48-2.43 (m, 1H), 1.46 (s, 36H), 1.35-1.25 (m, 12H). $^{13}$C NMR (100 MHz, $CDCl_3$) δ: 172.01, 170.43, 170.19, 170.14, 169.93, 155.71, 155.63, 131.30, 131.00, 129.34, 129.26, 128.92, 128.84, 121.62, 121.54, 116.34, 82.29, 82.07, 81.55, 64.04, 63.79, 57.90, 55.64, 50.37, 49.02, 43.23, 42.60, 38.49, 37.78, 37.50, 30.87, 30.64, 30.45, 28.03, 16.30, 16.26, 16.22. HRMS calcd for $C_{55}H_{90}N_4O_{18}P_2$ 1156.5725, found: 1157.7476 $[M + H]^+$.

**6f:** Following the general procedure, treatment of **5** (200 mg, 0.31 mmol) with *L*-glutamic acid di-tert-butyl ester hydrochloride (91 mg, 0.31 mmol) afforded **6f** (118 mg, 32.8%) as a colorless oil. $^{1}$H NMR (400 MHz, $CDCl_3$) δ: 7.03-6.99 (m, 2H), 6.76-6.74 (m, 4H), 5.13-4.99 (m, 1H), 4.22-4.10 (m, 8H), 3.69 (s, 4H), 3.47 (s, 1H), 3.18 (s, 4H), 2.87-2.85 (m, 4H), 2.69 (s, 4H), 2.49-2.44 (s, 4H), 2.29-2.13 (m, 2H), 2.11-2.05 (m, 1H), 1.92-1.82 (m, 1H), 1.46 (s, 36H), 1.35-1.26 (m, 12H). $^{13}$C NMR (100 MHz, $CDCl_3$) δ: 172.25, 172.08, 171.41, 171.24, 170.00, 155.94, 155.74, 131.33, 130.92, 129.11, 128.88, 121.56, 116.39, 82.21, 82.06, 82.04, 63.67, 57.97, 55.56, 52.16, 50.32, 43.33, 38.55, 38.00, 3.52, 30.65, 30.46, 28.07, 28.05, 27.98, 27.71, 16.35, 16.32, 16.28. HRMS calcd for $C_{56}H_{92}N_4O_{18}P_2$ 1170.5882, found:1171.5891 $[M + H]^+$.

**General synthetic procedures for 1a-f**

**[0056]** To a stirred solution of **6a-f** in acetonitrile (1 mL), bromotrimethylsilane was added, and the mixture continued stirring at room temperature overnight. The solvent was then removed under vacuum, trifluoroacetic acid (TFA) (2 mL) was added, and the reaction was again stirred at room temperature overnight. The mixture was then removed under vacuum, and the residue was recrystallized from ether/EtOH to yield **1a-f** as a white solid.

**1a**: Following the general procedure, treatment of **6a** (50 mg, 0.054 mmol) with bromotrimethylsilane (73 mg, 0.47 mmol) gave **1a** (31 mg, 82.3%) as a white solid. $^{1}$HNMR (400 MHz, dimethyl sulfoxide, DMSO-*d6*) δ: 7.90-7.86 (m, 4H), 7.36-7.33 (m, 2H), 3.77-3.75 (m, 5H), 3.33-3.29 (m, 6H), 2.66-2.61 (m, 4H).

**1b**: Sodium methylate (25 mg, 0.47 mmol) was mixed and stirred with **6b** (60 mg, 0.047 mmol) dissolved in methanol (5 mL) at room temperature for 2 h. Deprotection was monitered by LC-MS, and the reaction was neutralized by 1N HCl until pH = 7. Most of the solvent was then removed under vacuum and extracted with ethyl acetate. The crude product was dried over $MgSO_4$ without further purification and dissolved in acetonitrile (1.0 mL) before bromotrimethylsilane (1.0 mL) was added. The mixture was then stirred at room temperature overnight before the solvent was removed under vacuum, ether was added, filtered, and the solid was collected. The solid was then dissolved in TFA (2 mL), and the reaction was stirred at room temperature overnight. The above mixture was removed under vacuum, and the residue was recrystallized from ether/EtOH to give **1b** as a light yellow solid. $^{1}$HNMR (400 MHz, DMSO-*d6*) δ: 7.91 (s, 1H), 7.34-7.06 (m, 5H), 6.80-6.77 (m, 2H), 4.02-3.89 (m, 10H), 3.62-3.56 (m, 5H), 3.23-3.16 (m, 5H), 2.72-2.70 (m, 4H), 2.45-2.34 (m, 2H), 2.05-1.98 (m, 2H). $^{13}$C NMR (100 MHz, DMSO-*d6*) δ: 173.17, 171.41, 171.11, 170.72, 158.72, 158.40, 155.08, 154.77, 132.38, 131.91, 131.43, 130.28, 119.49, 118.97, 115.89, 115.72, 65.36, 55.34, 52.80, 51.69, 50.13, 35.64, 30.64, 21.60, 21.11, 15.61.

**1c**: Following the general procedure, treatment of **6c** (50 mg, 0.047 mmol) with bromotrimethylsilane (73 mg, 0.47 mmol) afforded **1c** (29 mg, 80.1%) as a white solid. $^{1}$HNMR (400 MHz, DMSO-*d6*) δ: 7.11-7.09 (m, 4H), 6.73-6.70 (m, 2H), 3.71 (s, 4H), 3.46 (s, 1H), 2.98-2.68 (m, 8H), 2.51-2.41 (m, 10H). $^{13}$CNMR (100 MHz, DMSO-*d6*) 174.95, 173.86, 172.99, 161.24, 154.93, 132.73, 118.37, 116.20, 115.11, 4.18, 49.61, 40.91, 30.03, 21.32.

**1d**: Following the general procedure, treatment of **6d** (50 mg, 0.047 mmol) with bromotrimethylsilane (73 mg, 0.47 mmol) afforded **1d** (30 mg, 81.5%) as a white solid. $^{1}$HNMR (400 MHz, DMSO-*d6*) δ: 7.09-7.05 (m, 4H), 6.78-6.75 (m, 2H), 3.70 (s, 4H), 3.42 (s, 1H), 2.73-2.68 (m, 6H), 2.54-2.45 (m, 10H), 1.36-1.32 (m, 3H). $^{13}$CNMR (100 MHz, DMSO-*d6*) δ: 174.71, 172.28, 171.96, 170.82, 159.13, 155.07, 132.38, 132.26, 130.40, 118.66, 15.89, 115.79, 65.36, 56.62, 47.88, 22.87, 18.93.

**1e**: Following the general procedure, treatment of **6e** (50 mg, 0.043 mmol) with bromotrimethylsilane (65 mg, 0.43 mmol) afforded **1e** (30 mg, 81.3%) as a white solid. $^{1}$HNMR (400 MHz, DMSO-*d6*) δ: 8.18 (s, 1H), 7.13-7.01 (m, 4H), 6.81-6.78 (m, 2H), 3.36-3.31 (s, 2H), 3.20 (s, 6H), 2.73-2.66 (m, 6H), 2.56-2.54 (m, 2H), 2.45 (s, 4H), 2.37-2.34 (m, 4H). $^{13}$C NMR (100 MHz, DMSO-*d6*) δ: 172.96, 172.13, 171.94, 170.59, 158.86, 158.50, 158.14, 155.02, 154.89, 65.36, 56.49, 49.03, 37.44, 36.55, 30.58, 19.00, 15.61.

**1f**: Following the general procedure, treatment of **6f** (50 mg, 0.042 mmol) with bromotrimethylsilane (65 mg, 0.42 mmol) gave **1f** (29 mg, 80.9%) as a white solid. $^{1}$HNMR (400 MHz, DMSO-*d6*) δ: 7.11-7.08 (m, 4H), 6.72-6.69 (m, 2H), 3.72 (s, 4H), 3.45 (s, 1H), 3.31 (s, 1H), 2.72-2.68 (m, 6H), 2.51-2.45 (m, 6H), 2.39-2.34 (m, 4H). $^{13}$CNMR (100 MHz, DMSO-*d6*) δ: 174.71, 172.28, 171.96, 170.82, 159.13, 158.81, 158.49, 154.95, 154.79, 132.38, 132.26, 130.40, 118.66, 115.89, 115.79, 65.36, 56.52, 47.88, 22.87, 18.93, 17.61.

**Synthesis of 1g**

**[0057]** To a stirred solution of **5** (50 mg, 0.054 mmol) and (*S*)-di-*tert*-butyl 2-(3-((*S*)-6-(6-aminohexanamido)-1-*tert*-butoxy-1-oxohexan-2-yl)ureido)pentanedioate (20 mg, 0.11 mmol) in 20 mL DMF, 1 ml N,N-diisopropylethylamine, HOBt (15 mg, 0.11 mmol) and EDCI (118 mg, 0.62 mmol) were added sequentially. The mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc (50 mL), washed with brine (2 × 20 mL), dried over $Na_2SO_4$, concentrated, and purified by FC (DCM/MeOH = 10/1) to yield a crude product **6g** (46 mg, 61.2%). To a stirred solution of **6g** (30 mg, 0.021 mmol) in 1 mL acetonitrile, bromotrimethylsilane (16 mg, 0.1 mmol) was added. The mixture was stirred at room temperature overnight, the solvent was removed under vacuum, TFA (4 mL) was added, and the reaction was stirred at room temperature overnight. The above mixture was then removed under vacuum, and the residue was recrystallized from ether/EtOH to yield **1g** as a white solid product (21 mg, 86.4%). $^{1}$HNMR (400 MHz, DMSO$_{-d6}$) δ: 7.85-7.69 (m, 2H), 7.18-7.08(m, 4H), 6.89-6.67 (m, 2H), 6.89-6.67 (m, 1H), 6.34 (s, 1H), 3.49-3.21 (m, 10H), 2.89-2.65 (m, 10H), 2.49-2.18 (m, 7H), 2.19-1.88 (m, 6H), 1.77-1.55 (m, 4H), 1.48-1.09 (m, 8H). $^{13}$CNMR (100 MHz, DMSO$_{-d6}$) $^{13}$C NMR (100 MHz, $CDCl_3$) δ: 177.48, 174.95, 174.58, 174.17, 172.49, 171.85, 171.50, 170.40, 170.12, 159.31, 158.95, 158.58, 157.79, 154.99, 132.55, 132.39, 130.63, 120.39, 118.51, 117.50, 115.91, 114.61, 111.71, 65.35, 60.21, 56.50, 52.75, 52.15, 35.82, 30.36, 29.28, 27.99, 25.49, 23.08, 18.97, 15.59.

**Synthesis of 1h**

**[0058]** To a stirred solution of compound **6a** (0.4 g, 0.43 mmol) and compound **2-Aminoethyl-mono-amide-DOTA-tris(t-Bu ester)** (0.29 g, 0.43 mmol) in 20 mL DMF, 2 mL DIEPA, HOBt(6 mg, 0.043 mmol) and EDCI(0.16 g, 0.86 mmol) were added sequentially. The reaction was stirred at room temperature for overnight. The mixture was diluted with 100 mLEtOAc, washed with brine (25 × 2 mL), dried over $Na_2SO_4$, concentrated and purified by combiflash (DCM/MeOH/$NH_4OH$ = 90/9/1) to give **6h** as white foam (0.39 g, 60%). $^1$HNMR(400 MHz, $CDCl_3$) δ: 8.04(s, 1H), 7.90(s, 1H), 6.80-6.82(m, 2H), 6.65(s, 1H), 6.62(s, 1H), 6.53(t, *J* = 8.2 Hz, 2H), 4.96-4.84(m, 1H), 4.00-3.92(m, 8H), 3.50(s, 4H), 3.23-3.15(m, 16H), 3.03(s, 6H), 2.68-2.62(m, 8H), 2.49(s, 6H), 2.41-2.31(m, 8H), 1.28(s, 45H),1.16-1.09(m, 3H). $^{13}$C NMR (100 MHz, $CDCl_3$) δ: 173.64, 172.33, 172.04, 171.67, 170.06, 155.44, 155.13, 131.83, 131.00, 129.25, 129.10, 128.83, 128.67, 121.26, 116.03, 115.84, 81.80, 81.77, 81.73, 81.67, 77.33, 77.01, 63.56, 63.54, 57.68, 57.55, 55.89, 55.52, 55.45, 55.29, 53.96, 52.58, 49.94, 43.25, 42.25, 39.14, 38.99, 38.10, 37.51, 30.87, 30.32, 27.83, 27.78, 27.72, 16.16, 16.13, 16.10, 16.07. HRMS calcd for $C_{73}H_{125}N_9O_{21}P_2$ 1525.8465; found, 1526.8258$[M+H]^+$. To a stirred solution of **6h (0.4 g, 0.26 mmol)** in 10 mL acetonitrile, 1.5 mL bromotrimethylsilane was added. The mixture continued stirring at room temperature overnight. The solvent was then removed under vacuum, TFA (4 ml) was added, and the reaction was, again, stirred at room temperature overnight. The mixture was then removed under vacuum, and the residue was purified EZ combflash **1h** (0.27 g, 93.1%).$^1$HNMR(400 MHz, $CDCl_3$) δ: $^{13}$C NMR (100 MHz, $CDCl_3$) δ 172.44, 172.10, 169.95, 159.37, 159.01, 158.63, 155.14, 132.84, 132.45, 130.98, 120.08, 117.19, 116.01, 114.31, 111.44, 69.35, 65.36, 60.21, 56.48, 55.20, 54.34, 53.00, 51.68, 51.05, 49.63, 48.93, 48.43, 30.60, 22.90, 21.21, 20.92, 18.99, 15.61, 14.54, 13.92 HRMS calcd for $C_{45}H_{69}N_9O_{21}P_2$ 1133.4083; found, 1134.4131$[M+H]^+$.

**Scheme 2**

**Preparation of [$^{nat}Ga^{3+}$]1a**




**1a** **[$^{nat}$Ga]1a**

**Example 2**

**Synthesis of compound [$^{nat}Ga^{3+}$]1a**

**[0059]** As shown in Scheme 2, $GaCl_3$ (1.7 mg, 0.01 mmol) in 0.1 mL $H_2O$ was added to a solution of **1a** (7 mg, 0.01 mmol) in DMSO (0.5 mL). The reaction solution was adjusted to pH

4 and stirred at room temperature overnight. The solution was then evaporated under vacuum, and the crude product was recrystalled from ethanol and $H_2O$ to yield **[$^{nat}Ga^{3+}$]1a** as a white solid (6.8 mg, 90.2%). $^1$HNMR (400 MHz, DMSO-*d6*) δ: 7.38 (s, 1H), 7.25-7.20 (m, 4H), 6.88 (s, 1H), 3.61-3.52 (m, 4H), 3.49 (s, 2H), 3.33-3.15 (m, 6H), 2.71 (s, 4H), 2.55 (s, 2H), 2.45 (s, 2H). $^{13}$C NMR (400 MHz, DMSO-*d6*) δ: 174.39, 173.04, 171. 69, 168.39, 168.23, 155.46, 155.36, 133.53, 132.49, 132.12, 131.80, 117.00, 116.19, 115.51, 70.19, 53.10, 49.04, 37.26, 35.90, 29.83, 22.64.

**Scheme 3**

**Synthesis of 2,2'-(ethane-1,2-diylbis((5-(3-((diphosphonomethyl)amino)-3-oxopropyl)-2-hydroxybenzyl)azanediyl))diacetic acid (2)**




**Example 3**

**Synthesis of compound 2**

**1. ((3-(3-(((2-((5-(3-((bis(diethoxyphosphoryl)methyl)amino)-3-oxopropyl)-2-hydroxybenzyl)(2-(*tert*-butoxy)-2-oxoethyl)amino)ethyl)(2-(*tert*-butoxy)-2-oxoethyl) amino)methyl)-4-hydroxyphenyl)propanamido) methylene)diphosphonic acid (7)**

**[0060]** As summarized in Scheme 3, triethyl amine (2 mL), HOBt (44 mg, 0.33 mmol), and HBTU (129 mg, 0.34 mmol) were added sequentially to a stirred solution of **5** (100 mg, 0.15 mmol) and tetraethyl aminomethylenediphosphonate (52 mg, 0.33 mmol) in 20 mL DMF. The mixture was stirred at room temperature overnight, diluted with EtOAc (50 mL), washed with brine (20 × 2 mL), dried over $Na_2SO_4$, concentrated, and purified by FC (DCM/MeOH/$NH_4OH$ = 90/9/1) to yield 7 as a white foam (116 mg, 41.2%). $^1$HNMR (400 MHz, $CDCl_3$) δ: 7.01 (t, *J* = 3.6 Hz, 12H), 6.78-6.75 (m, 4H), 4.22-4.14 (m, 16H), 3.71 (s, 4H), 3.18 (s, 4H), 2.89-2.85 (m, 6H), 2.70 (s, 4H), 2.56-2.52 (t, *J* = 3.6 Hz, 4H), 1.46 (s, 18H), 1.36-1.30 (m, 24H). HRMS calcd for $C_{52}H_{90}N_4O_{20}P_4$ 1214.5099; found 1215.5061 $[M+H]^+$.

**2. 2,2'-(ethane-1,2-diylbis((5-(3-((diphosphonomethyl)amino)-3-oxopropyl)-2-hydroxybenzyl)azanediyl))diacetic acid (2)**

**[0061]** To a stirred solution of 7 (60 mg, 0.049 mmol) in acetonitrile (1 mL), bromotrimethylsilane (75 mg, 0.49 mmol) was added. The mixture was stirred at room temperature overnight, the solvent was removed under vacuum, and TFA (2 mL) was added before the reaction was, again, stirred at room temperature overnight. The mixture was then removed under vacuum, and the residue was recrystallized from ether/EtOH to yield **2** as a white solid (34 mg, 82.1%). $^1$HNMR (400 MHz, DMSO-*d6*) δ: 7.24-7.20 (m, 4H), 6.88 (d, *J* = 4.32 Hz, 2H), 4.41-4.37 (m, 4H), 3.87 (s, 2H), 2.88-2.81 (m, 6H), 2.61-2.68 (m, 4H), 2.35-2.33 (m, 4H).

Scheme 4

**2,2'-(((((propane-1,3-diylbis(azanediyl))bis(3-oxopropane-3,1-diyl))bis(2-hydroxy-5,1-phenylene))bis(methylene))bis((2-((carboxymethyl)(5-(3-((diphosphonomethyl) amino)-3-oxopropyl)-2-hydroxybenzyl)amino )ethyl)azanediyl))diacetic acid (3)**




**Example 4**

**Synthesis of compound 3**

**1. Di-*tert*-butyl 2,2'-(((((propane-1,3-diylbis(azanediyl))bis(3-oxopropane-3,1-diyl))bis(2-hydroxy-5,1-phenylene))bis(methylene))bis((2-((5-(3-((bis(diethoxy phosphoryl)methyl)amino)-3-oxopropyl)-2-hydroxybenzyl)(2-(*tert*-butoxy)-2-**

**oxoethyl)amino)ethyl)azanediyl)) diacetate (8)**

**[0062]** To a stirred solution of **1a** (50 mg, 0.054mmol) and 1,3-diaminopropane (2 mg, 0.027 mmol) in 10 mL DMF, triethyl amine (2 mL), HOBt (14 mg, 0.11 mmol), and EDCI (40 mg, 0.22 mmol) were added sequentially, as shown in Scheme 4. The mixture was stirred at room temperature overnight, diluted with EtOAc (50 mL), washed with brine (2 × 20 mL), dried over $Na_2SO_4$, concentrated, and purified by FC (DCM/MeOH/$NH_4OH$ = 90/9/1) to yield **8** as a white foam (27 mg, 53.2%). HRMS calcd for $C_{90}H_{146}N_8O_{28}P_4$ [M]+2H$^+$ 949.9577; found 949.9581 [M]+2H$^+$.

**2. 2,2'-(((((propane-1,3-diylbis(azanediyl))bis(3-oxopropane-3,1-diyl))bis(2-hydroxy-5,1-phenylene))bis(methylene))bis((2-((carboxymethyl)(5-(3-((diphosphonomethyl) amino)-3-oxopropyl)-2-hydroxybenzyl)amino)ethyl)azanediyl))diacetic acid (3)**

**[0063]** To a stirred solution of **8** (20 mg, 0.01 mmol) in acetonitrile (1 mL), bromotrimethylsilane (16 mg, 0.1 mmol) was added, and the mixture was stirred at room temperature overnight. The solvent was removed under vacuum, TFA (2 mL) was added, and the reaction was, again, stirred at room temperature overnight. The mixture was then removed under vacuum, and the residue was recrystallized from ether/EtOH to yield **3** as a white solid product (12 mg, 81.5%). $^1$HNMR (400 MHz, DMSO-*d6*) δ: 7.11-7.07 (m, 8H), 6.74-6.68 (m, 4H), 3.73 (s, 8H), 3.43 (s, 2H), 3.08-2.92 (m, 8H), 2.82-2.72 (m, 12H), 2.67-2.56 (m, 10H), 2.49-2.31 (m, 8H).

**Example 5**

**Radiolabeling with $^{68}$Ga**

**[0064]** Gallium-68 eluted in a 0.05 N HCl solution was obtained from a $^{68}$Ge/$^{68}$Ga generator (iTG, Germany). Preparation of $^{68}$Ga labeled BPAMD was accomplished using the labeling procedures previously reported.

**Scheme 5**: $^{68}$Ga labeling of compounds **1a-h**






**Scheme 6**: $^{68}$Ga labeling of compounds **2**




**Scheme 7:** $^{68}$Ga labeling of compound **3**




**[0065]** To prepare the new HBED-CC bisphosphonate derivatives for $^{68}$Ga labeling, a stock solution of ligands **1a-h** (200 µM in 0.1 N NaOAc), **2** (200 µM in 0.1 N NaOAc), and **3** (200 µM in 0.1 N NaOAc) were prepared and used for each study. $^{68}$Ga labeling was performed by adding the $^{68}$Ga solution to different solutions of ligands **1a-h, 2,** and **3** as seen in Schemes 5-7. Labeling conditions for **1a-h, 2,** and **3** were, 200 µL of $^{68}GaCl_3$ in 0.05 N HCl and a 200 µM ligand solution of **1a-h, 2,** or **3** (250 µL) in 0.1 N NaOAc maintained at room temperature for 10 min (final concentration: 111 µM, pH 5.0). Radiolabeling yields were determined after holding the reaction mixture at room temperature for 5-10 min. Radiochemical yields for **[$^{68}$Ga]1a-h, [$^{68}$Ga]2,** and **[$^{68}$Ga]3** were determined by Macherey Nagel cellulose TLC plates (Polygram Cel 300) developed with a solvent mixture consisting of 2 parts, 0.1 N NaOAc (10 mL, pH 4.10, 88 mL acetone), and 1 part, 2,4-pentadione. The activity distribution on each TLC plate was

measured by autoradiography using a Typhoon FLA 7000 laser scanner. The HPLC analysis was performed using a C18 column (Supelco Ascentis C18 150 × 4.6 mm 5µ, MeOH: 0.1% TFA in $H_2O$ (gradient: 0 min, 100% 0.1% TFA in $H_2O$; 6 min, 0% 0.1% TFA in $H_2O$, flow rate, 2 mL/min).

**[0066]** For in vivo imaging studies, a larger amount of $^{68}Ga$ labeled agents was needed. The labeling was performed in an aqueous NaOAc buffer (200 µL, 2.0 M) by adding a ligand solution (200 µL, 200 µM in 0.1 N NaOAc) to a $^{68}Ga$ solution (400 µL in 0.6 N HCl) in $H_2O$ (200 µL). The final pH of the solution was 4.10.

**Example 6**

**In vivo biodistribution in mice**

**[0067]** Biodistribution experiments were performed by intravenously administering $^{68}Ga$ labeled **1a-h, 2, 3,** BPAMD, and [$^{18}F$]NaF into normal, healthy male CD-1 mice (25-30 g). The injection activity was 20-30 µCi/animal. Animals were sacrificed at 2, 30, 60, and 120 min post injection. Organs of interest were harvested, weighed, and counts of radioactivity were measured by a gamma counter. The biodistribution of each sample was calculated as a percentage of the injected dose per gram of wet tissue weight (% ID/g). Tibia and femur bones were harvested and counted as bone samples.

**Example 7**

**In vitro binding to hydroxyapatite**

**[0068]** Hydroxyapatite (20 mg, Sigma-Aldrich, reagent grade powder) was incubated in isotonic saline (1 mL) for 24 h. Subsequently, either $^{68}Ga$ labeled **1a-h, 2, 3,** BPAMD, or [$^{18}F$]NaF (1 µCi) was added to the hydroxyapatite suspension. After vortexing for 10 seconds, the suspension was incubated for 10 min at room temperature. The samples were then centrifuged at 10,000 rpm for 3 min and the supernatant was removed. The hydroxyapatite fraction was washed twice with saline (1 mL). Radioactivity in the combined supernatants and the hydroxyapatite fraction was measured using a gamma counter. The proportion of the $^{68}Ga$ complex binding to hydroxyapatite was determined as percent of $^{68}Ga$ absorbed to hydroxyapatite.

**Example 8**

**Micro-PET imaging studies in mice**

**[0069]** [$^{68}$Ga]1a, [$^{68}$Ga]BPAMD and [$^{18}$F]NaF were tested in normal CD-1 male mice. [$^{68}$Ga] 1g was tested in PSMA expressing LNCaP tumor bearing nude mice. Mice received 300-500 uCi radiotracer through a tail vein injection. PET imaging was performed under isoflurane anaesthesia (2% isoflurane, 1.5 L/min oxygen). The microPET imaging was performed with a small animal PET (Mosaic by Phillips, USA). During PET measurements, the animals were placed in the prone position. At 60 min post injection of the radiotracer, data acquisition was performed for 15 min.

**Results**

**Synthesis**

**[0070]** Synthesis of target compounds **1a-h, 2,** and **3** were prepared by the reactions described in Schemes 1, 3, and 4. In order to prepare a protected compound **5,** compound **4** was synthesized by a Mannich reaction with di-*tert*-butyl 2,2'-(ethane-1,2-diylbis(azanediyl))diacetate and methyl 3-(4-hydroxyphenyl)propanoate in excellent yield (84.5%). The carboxylic functional groups of **4** were separately protected by either an OtBu or OMe ester group, The methyl ester of compound **4** was selectively removed by NaOH hydrolysis to give compound **5** (94.7% yield). To make bisphosphonate derivatives, compound **5** was activated with EDCI and HOBt in DMF. The addition of tetraethyl aminomethylenediphosphonate gave the desired protected bisphosponate, **6a,** in 44.3% yield. After treatment of **6a** with trimethylbromosilane at room temperature overnight, removal of the solvent, and stirring in TFA for another night, the phosphonate ethyl ester groups and the t-butyl esters were removed simultaneously to give **1a** (82.3% yield).

**[0071]** In order to produce **6c** which bears a different group, an amino acid group was added to the protected HBED-CC **5** core first in order to produce an intermediate, because tetraethyl aminomethylenediphosphonate has a greater steric hindrance compared to the protected amino acid. A further intermediate reaction was conducted with tetraethyl aminomethyl-enediphosphonate to yield **6c.** After treatment of **6c** with trimethylbromosilane and TFA using a similar method to **1a, 6c** was obtained in 80.1% yield. This approach was simple and versatile. Using a similar reaction sequence and a different derivatives, **1b-h** were prepared. The synthesis of the desired bisphosphonates was successfully accomplished and easily controlled.

**Radiolabeling of 1a-h, 2 and 3 using $^{68}GaCl_3$**

**[0072]** The preparation of radioactive [$^{68}$Ga]**1a-h**, [$^{68}$Ga]**2**, and [$^{68}$Ga]**3** was accomplished by mixing $^{68}GaCl_3$ in 0.05 M HCl with a suitable amount of precursor **1a-h, 2,** or **3** in a 0.1 N NaOAc solution and maintaining the reaction at room temperature for 10 minutes. The radiochemical purity was measured by both TLC and HPLC methods. TLC results showed that the $^{68}$Ga complex exhibited Rf = 0-0.1 and the free $^{68}Ga^{3+}$ product displayed Rf = 0.8-0.9. As expected, HPLC analysis revealed multiple peaks for the Ga-HBED-CC-BP complexes. **[$^{68}$Ga]1a-h, [$^{68}$Ga]2,** and **[$^{68}$Ga]3** showed a retention time of 4-5.5 min, while free $^{68}GaCl_3$ showed a retention time of 1 min.

**[0073]** The **[$^{nat}$Ga]1a** ligand was synthesized by reacting **1a** with $GaCl_3$ in DMSO at room temperature overnight. The compound was then characterized spectroscopically.

**[0074]** Importantly, the preparation of [$^{68}$Ga]**1a-h** and [$^{68}$Ga]**2** can be readily achieved at room temperature in 5 to 10 minutes at a ligand concentration of 111 μM, whereas the preparation of the known agent, [$^{68}$Ga]BPAMD, required heating at 80-90 °C for 5-10 min. The new bone imaging agents, [$^{68}$Ga]**1a-h** and [$^{68}$Ga]**2**, may provide a kit formulation, which can be conveniently adopted in nuclear medicine clinics without the need for heating, cooling, and a nearby cyclotron for production of [$^{18}$F]NaF.

**[0075]** A proper metal ion, such as Lu(III) chloride, can be identified for selective radiolabeling of the DOTA moiety of compound **1h** based on difference in the metal's complexing capability and stability constants for metal complexes with DOTA and HBED. The conditions for the selective radiolabeling can be routinely optimized under a similar reaction condition as described above for $^{68}$Ga(III), except that the reception may require heating the reaction mixture of $^{177}$Lu(III) and the ligand, **1h.**

**In vivo biodistribution in normal mice**

**[0076]** To evaluate bone uptake, $^{68}$Ga labeled complexes and known bone imaging agent, [$^{18}$F]NaF, were injected intravenously into normal mice. The results of a biodistribution study displayed in Table 4 show that the bone uptake for [$^{18}$F]NaF, [$^{68}$Ga]**1a**, and [$^{68}$Ga]**2** at 60 min post iv injection in normal mice was 24.6 ± 3.2, 23.5 ± 1.4 and 19.7 ± 4.2 (%dose/g), respectively. The bone/muscle indicating signal/background ratio in normal mice for [$^{18}$F]NaF, [$^{68}$Ga]**1a**, and [$^{68}$Ga]**2** at 60 min post iv injection was 291, 94.5 and 82.7, respectively. It is demonstrated that [$^{68}$Ga]BPAMD exhibited less bone uptake and retention as compared to the new agents, [$^{68}$Ga]**1a-h** and [$^{68}$Ga]**2**. In particular, [$^{68}$Ga]**1a**, [$^{68}$Ga]**1g**, [$^{68}$Ga]**1h** and [$^{68}$Ga]**2**

demonstrated excellent bone uptake and fast kidney excretion compared to that observed for [$^{18}$F]NaF. The results suggest that [$^{68}$Ga]**1a**, [$^{68}$Ga]**1g**, [$^{68}$Ga]**1h** and [$^{68}$Ga]**2**, will likely be comparable in imaging human bone uptake and perhaps bone metastasis, similar to the current agent of choice [$^{18}$F]NaF.

**Table 4a-g:** Biodistribution of bone imaging agents : [$^{18}$F]NaF, [$^{68}$Ga]BPAMD, [$^{68}$Ga]**1a-h**, [$^{177}$Lu]**1h**, [$^{68}$Ga]**2**, [$^{68}$Ga]**3**, and [$^{68}$Ga]**HBED-CC** in normal CD-1 male mice (%dose/g, Avg ± SD of n=3)

| **a.** Radiotracer: [$^{18}$F]NaF | | | | |
|---|---|---|---|---|
| | 2 min | 30 min | 60 min | 120 min |
| Blood | 5.56 ± 0.37 | 0.64 ± 0.08 | 0.15 ± 0.01 | 0.03 ± 0.00 |
| Heart | 2.80 ± 0.24 | 0.96 ± 0.23 | 0.18 ± 0.02 | 0.04 ± 0.00 |
| Muscle | 1.50 ± 0.06 | 0.33 ± 0.11 | 0.09 ± 0.02 | 0.04 ± 0.04 |
| Lung | 3.37 ± 0.17 | 0.55 ± 0.11 | 0.14 ± 0.01 | 0.04 ± 0.01 |
| Kidney | 10.4 ± 1.22 | 1.70 ± 0.62 | 0.68 ± 0.36 | 0.57 ± 0.43 |
| Spleen | 2.33 ± 0.14 | 0.93 ± 0.56 | 0.12 ± 0.02 | 0.03 ± 0.01 |
| Pancreas | 1.76 ± 0.07 | 0.42 ± 0.27 | 0.07 ± 0.00 | 0.02 ± 0.00 |
| Liver | 2.56 ± 0.24 | 0.65 ± 0.17 | 0.13 ± 0.01 | 0.03 ± 0.01 |
| Skin | 2.35 ± 0.45 | 0.51 ± 0.11 | 0.11 ± 0.02 | 0.03 ± 0.00 |
| Brain | 0.22 ± 0.07 | 0.10 ± 0.02 | 0.06 ± 0.01 | 0.04 ± 0.00 |
| **Bone** | **10.8 ± 0.51** | **24.2 ± 2.71** | **24.6 ± 3.18** | **25.2 ±3.89** |
| **b.** Radiotracer: [$^{68}$Ga]BPAMD | | | | |
| | 2 min | 30 min | 60 min | 120 min |
| Blood | 9.45 ± 0.55 | 1.02 ± 0.19 | 0.93 ± 0.06 | 0.90 ± 0.41 |
| Heart | 2.74 ± 0.23 | 0.29 ± 0.02 | 0.37 ± 0.06 | 0.26 ± 0.07 |
| Muscle | 1.63 ± 0.35 | 0.55 ± 0.11 | 0.31 ± 0.04 | 0.29 ± 0.06 |
| Lung | 4.58 ± 0.36 | 0.50 ± 0.16 | 0.51 ± 0.09 | 0.45 ± 0.10 |
| Kidney | 22.1 ± 8.80 | 1.46 ± 0.19 | 2.88 ± 1.51 | 1.09 ± 0.26 |
| Spleen | 1.90 ± 0.14 | 0.22 ± 0.14 | 0.21 ± 0.02 | 0.25 ± 0.08 |
| Pancreas | 1.73 ± 0.11 | 0.27 ± 0.14 | 0.30 ± 0.02 | 0.33 ± 0.07 |
| Liver | 1.92 ± 0.31 | 0.22 ± 0.02 | 0.25 ± 0.03 | 0.31 ± 0.11 |
| Skin | 2.57 ± 0.53 | 0.39 ± 0.15 | 0.60 ± 0.08 | 0.55 ± 0.04 |
| Brain | 0.26 ± 0.01 | 0.06 ± 0.02 | 0.04 ± 0.00 | 0.03 ± 0.01 |
| **Bone** | **7.07 ± 0.94** | **10.5 ± 0.6** | **9.21 ± 0.90** | **9.62 ± 0.71** |

| **c.** Radiotracers: [$^{68}$Ga]1a | | | | |
|---|---|---|---|---|
| | 2 min | 30 min | 60 min | 120 min |
| Blood | 9.39 ± 0.93 | 0.45 ± 0.10 | 0.20 ± 0.06 | 0.07 ± 0.03 |
| Heart | 3.28 ± 0.13 | 0.22 ± 0.02 | 0.12 ± 0.02 | 0.07 ± 0.01 |
| Muscle | 1.80 ± 0.16 | 0.17 ± 0.03 | 0.08 ± 0.02 | 0.05 ± 0.01 |
| Lung | 4.28 ± 0.21 | 0.38 ± 0.03 | 0.21 ± 0.03 | 0.12 ± 0.03 |
| Kidney | 31.2 ± 1.92 | 1.54 ± 0.29 | 1.63 ± 0.71 | 0.92 ± 0.10 |
| Spleen | 1.89 ± 0.20 | 0.17 ± 0.01 | 0.10 ± 0.02 | 0.09 ± 0.03 |
| Pancreas | 1.58 ± 0.10 | 0.30 ± 0.27 | 0.09 ± 0.02 | 0.05 ± 0.01 |
| Liver | 1.95 ± 0.15 | 0.32 ± 0.20 | 0.17 ± 0.01 | 0.14 ± 0.02 |
| Skin | 2.18 ± 0.28 | 0.42 ± 0.12 | 0.19 ± 0.05 | 0.13 ± 0.03 |
| Brain | 0.31 ± 0.10 | 0.02 ± 0.01 | 0.02 ± 0.01 | 0.01 ± 0.00 |
| **Bone** | **8.60 ± 0.85** | **16.0 ± 1.22** | **23.5 ± 1.42** | **23.9 ± 1.99** |
| **d.** Radiotracers: [$^{68}$Ga]1b | | | | |
| | 2 min | 30 min | 60 min | 120 min |
| Blood | 9.22 ± 0.83 | 0.83 ± 0.04 | 0.39 ± 0.06 | 0.21 ± 0.06 |
| Heart | 3.01 ± 0.23 | 0.62 ± 0.04 | 0.37 ± 0.02 | 0.28 ± 0.04 |
| Muscle | 1.79 ± 0.28 | 0.24 ± 0.03 | 0.13 ± 0.01 | 0.09 ± 0.01 |
| Lung | 5.11 ± 0.28 | 1.31 ± 0.29 | 0.96 ± 0.05 | 0.86 ± 0.03 |
| Kidney | 18.5 ± 2.45 | 3.21 ± 1.59 | 2.65 ± 0.44 | 2.71 ± 0.17 |
| Spleen | 2.03 ± 0.13 | 0.75 ± 0.22 | 0.66 ± 0.15 | 0.53 ± 0.04 |
| Pancreas | 1.51 ± 0.06 | 0.24 ± 0.02 | 0.11 ± 0.01 | 0.08 ± 0.01 |
| Liver | 2.58 ± 0.22 | 1.20 ± 0.10 | 1.15 ± 0.13 | 1.22 ± 0.07 |
| Skin | 2.55 ± 0.58 | 0.60 ± 0.02 | 0.26 ± 0.04 | 0.18 ± 0.01 |
| Brain | 0.20 ± 0.04 | 0.03 ± 0.01 | 0.02 ± 0.01 | 0.02 ± 0.01 |
| **Bone** | **8.34 ± 0.88** | **16.6 ± 1.37** | **19.4 ± 2.05** | **17.1 ± 3.70** |
| **e.** Radiotracers: [$^{68}$Ga]1c | | | | |
| | 2 min | 30 min | 60 min | 120 min |
| Blood | 11.7 ± 0.55 | 1.34 ± 0.32 | 0.64 ± 0.17 | 0.41 ± 0.07 |
| Heart | 4.57 ± 0.45 | 0.49 ± 0.07 | 0.24 ± 0.08 | 0.19 ± 0.03 |
| Muscle | 1.68 ±0.11 | 0.23 ± 0.05 | 0.14 ± 0.01 | 0.16 ± 0.01 |
| Lung | 5.66 ± 0.24 | 0.84 ± 0.11 | 0.42 ± 0.08 | 0.31 ± 0.06 |
| Kidney | 27.7 ± 5.46 | 2.58 ± 0.05 | 1.88 ± 0.10 | 2.05 ± 0.27 |
| Spleen | 3.41 ± 0.08 | 0.97 ± 0.01 | 0.74 ± 0.10 | 0.71 ± 0.29 |
| Pancreas | 1.99 ± 0.23 | 0.39 ± 0.05 | 0.23 ± 0.02 | 0.20 ± 0.03 |

| **e.** Radiotracers: [$^{68}$Ga]1c | | | | |
|---|---|---|---|---|
| | 2 min | 30 min | 60 min | 120 min |
| Liver | 4.78 ± 0.18 | 2.21 ± 0.27 | 1.85 ± 0.11 | 1.99 ± 0.09 |
| Skin | 2.05 ± 0.16 | 0.53 ± 0.18 | 0.33 ± 0.03 | 0.31 ± 0.04 |
| Brain | 0.27 ± 0.06 | 0.05 ± 0.02 | 0.03 ± 0.01 | 0.02 ± 0.01 |
| **Bone** | **8.40 ± 1.32** | **11.3 ± 0.26** | **14.7 ± 0.66** | **16.1 ± 2.71** |
| **f.** Radiotracers: [$^{68}$ Ga]1d | | | | |
| | 2 min | 30 min | 60 min | 120 min |
| Blood | 9.08 ± 0.58 | 0.53 ± 0.13 | 0.10 ± 0.01 | 0.06 ± 0.02 |
| Heart | 2.99 ± 0.26 | 0.26 ± 0.06 | 0.08 ± 0.01 | 0.06 ± 0.01 |
| Muscle | 1.72 ± 0.15 | 0.24 ± 0.06 | 0.06 ± 0.00 | 0.04 ± 0.01 |
| Lung | 4.83 ± 0.25 | 0.45 ± 0.10 | 0.17 ± 0.01 | 0.09 ± 0.02 |
| Kidney | 25.3 ± 3.89 | 2.14 ± 0.60 | 1.05 ± 0.17 | 0.91 ± 0.15 |
| Spleen | 1.72 ± 0.24 | 0.21 ± 0.07 | 0.06 ± 0.00 | 0.05 ± 0.01 |
| Pancreas | 1.53 ± 0.14 | 0.21 ± 0.12 | 0.06 ± 0.01 | 0.04 ± 0.01 |
| Liver | 1.89 ± 0.16 | 0.26 ± 0.09 | 0.12 ± 0.01 | 0.10 ± 0.01 |
| Skin | 2.39 ± 0.13 | 0.42 ± 0.10 | 0.13 ± 0.01 | 0.09 ± 0.01 |
| Brain | 0.29 ± 0.05 | 0.03 ± 0.00 | 0.01 ± 0.00 | 0.00 ± 0.00 |
| **Bone** | **10.1 ± 2.05** | **15.3 ± 1.26** | **14.7 ± 0.50** | **17.0 ± 1.10** |
| **g.** Radiotracers: [$^{68}$Ga]1e | | | | |
| | 2 min | 30 min | 60 min | 120 min |
| Blood | 8.31 ± 0.57 | 0.57 ± 0.12 | 0.11 ± 0.02 | 0.08 ± 0.02 |
| Heart | 2.55 ± 0.06 | 0.26 ± 0.04 | 0.08 ± 0.00 | 0.06 ± 0.01 |
| Muscle | 1.71 ± 0.19 | 0.25 ± 0.03 | 0.06 ± 0.00 | 0.04 ± 0.01 |
| Lung | 4.00 ± 0.20 | 0.42 ± 0.08 | 0.15 ± 0.01 | 0.12 ± 0.02 |
| Kidney | 24.8 ± 3.02 | 2.26 ± 0.27 | 2.12 ± 0.55 | 1.41 ± 0.28 |
| Spleen | 1.72 ± 0.19 | 0.19 ± 0.02 | 0.09 ± 0.01 | 0.06 ± 0.01 |
| Pancreas | 1.27 ± 0.07 | 0.17 ± 0.05 | 0.06 ± 0.01 | 0.04 ± 0.01 |
| Liver | 1.90 ± 0.13 | 0.27 ± 0.02 | 0.14 ± 0.01 | 0.14 ± 0.02 |
| Skin | 2.54 ± 0.26 | 0.86 ± 0.22 | 0.12 ± 0.01 | 0.12 ± 0.03 |
| Brain | 0.20 ± 0.04 | 0.02 ± 0.01 | 0.01 ± 0.00 | 0.01 ± 0.01 |
| **Bone** | **8.82 ± 0.77** | **16.5 ± 0.56** | **14.9 ± 1.45** | **17.6 ± 2.61** |
| **h.** Radiotracers: [$^{68}$Ga]1f | | | | |
| | 2 min | 30 min | 60 min | 120 min |
| Blood | 8.98 ± 0.68 | 0.52 ± 0.05 | 0.18 ± 0.04 | 0.09 ± 0.01 |

| **h.** Radiotracers: [$^{68}$Ga]1f | | | | |
|---|---|---|---|---|
| | 2 min | 30 min | 60 min | 120 min |
| Heart | 3.53 ± 0.57 | 0.23 ± 0.01 | 0.11 ± 0.01 | 0.07 ± 0.01 |
| Muscle | 2.10 ± 0.12 | 0.23 ± 0.01 | 0.06 ± 0.00 | 0.04 ± 0.01 |
| Lung | 5.01 ± 0.81 | 0.42 ± 0.03 | 0.21 ± 0.01 | 0.13 ± 0.01 |
| Kidney | 24.7 ± 3.13 | 2.05 ± 0.52 | 1.59 ± 0.72 | 1.08 ± 0.20 |
| Spleen | 2.20 ± 0.26 | 0.22 ± 0.03 | 0.12 ± 0.04 | 0.08 ± 0.01 |
| Pancreas | 1.96 ± 0.15 | 0.15 ± 0.01 | 0.08 ± 0.02 | 0.04 ± 0.00 |
| Liver | 2.43 ± 0.27 | 0.28 ± 0.02 | 0.20 ± 0.02 | 0.19 ± 0.01 |
| Skin | 2.62 ± 0.11 | 0.49 ± 0.04 | 0.15 ± 0.01 | 0.09 ± 0.01 |
| Brain | 0.22 ± 0.00 | 0.02 ± 0.00 | 0.01 ± 0.00 | 0.01 ± 0.01 |
| **Bone** | **8.62 ± 0.23** | **16.8 ± 1.66** | **14.4 ± 3.01** | **16.7 ± 1.12** |
| **i.** Radiotracers: [$^{68}$Ga] 1g | | | | |
| | 2 min | 30 min | 60 min | 120 min |
| Blood | 8.34 ± 0.51 | 0.56 ± 0.10 | 0.28 ± 0.05 | 0.17 ± 0.03 |
| Heart | 3.13 ± 0.15 | 0.45 ± 0.07 | 0.32 ± 0.03 | 0.20 ± 0.03 |
| Muscle | 2.19 ± 0.11 | 0.35 ± 0.02 | 0.21 ± 0.02 | 0.17 ± 0.04 |
| Lung | 4.19 ± 0.50 | 1.02 ± 0.13 | 0.58 ± 0.02 | 0.47 ± 0.04 |
| Kidney | 35.3 ± 3.75 | 77.1 ± 8.24 | 78.4 ± 7.11 | 70.3 ± 8.29 |
| Spleen | 2.50 ± 0.41 | 2.09 ± 0.75 | 0.91 ± 0.13 | 0.87 ± 0.20 |
| Pancreas | 1.69 ± 0.13 | 0.69 ± 0.02 | 0.37 ± 0.07 | 0.34 ± 0.03 |
| Liver | 1.73 ± 0.09 | 0.27 ± 0.02 | 0.18 ± 0.01 | 0.18 ± 0.02 |
| Skin | 2.97 ± 0.14 | 0.65 ± 0.05 | 0.42 ± 0.06 | 0.29 ± 0.06 |
| Brain | 0.21 ± 0.03 | 0.03 ± 0.00 | 0.03 ± 0.01 | 0.02 ± 0.00 |
| **Bone** | **8.13 ± 1.87** | **16.3 ± 0.68** | **15.1 ± 1.04** | **17.0 ± 0.05** |
| **j.** Radiotracers: [$^{68}$Ga]1h | | | | |
| | 2 min | 30 min | 60 min | 120 min |
| Blood | 9.69 ± 1.49 | 0.45 ± 0.07 | 0.11 ± 0.05 | 0.04 ± 0.01 |
| Heart | 3.10 ± 0.35 | 0.24 ± 0.12 | 0.08 ± 0.01 | 0.05 ± 0.01 |
| Muscle | 1.92 ± 0.14 | 0.14 ± 0.04 | 0.05 ± 0.01 | 0.03 ± 0.00 |
| Lung | 4.35 ± 0.52 | 0.31 ± 0.05 | 0.14 ± 0.03 | 0.10 ± 0.01 |
| Kidney | 18.2 ± 1.65 | 2.07 ± 0.62 | 1.13 ± 0.08 | 1.67 ± 0.54 |
| Spleen | 1.91 ± 0.48 | 0.13 ± 0.03 | 0.07 ± 0.01 | 0.07 ± 0.01 |
| Pancreas | 1.48 ± 0.27 | 0.09 ± 0.03 | 0.05 ± 0.02 | 0.04 ± 0.01 |
| Liver | 1.99 ± 0.29 | 0.15 ± 0.05 | 0.07 ± 0.01 | 0.09 ± 0.04 |

| **j.** Radiotracers: [$^{68}$Ga]1h | | | | |
|---|---|---|---|---|
| | 2 min | 30 min | 60 min | 120 min |
| Skin | 2.31 ± 0.25 | 0.39 ± 0.13 | 0.11 ± 0.02 | 0.07 ± 0.01 |
| Brain | 0.24 ± 0.03 | 0.02 ± 0.01 | 0.01 ± 0.00 | 0.01 ± 0.01 |
| **Bone** | **8.31 ± 0.84** | **12.1 ± 0.84** | **11.9 ± 1.31** | **12.0 ± 0.82** |
| **k.** Radiotracers: [$^{177}$Lu]1h | | | | |
| | 0.5 hr | 1 hr | 6 hr | 24 hr |
| Blood | 0.54 ± 0.11 | 0.12 ± 0.02 | 0.016 ± 0.007 | 0.003 ± 0.001 |
| Heart | 0.23 ± 0.05 | 0.08 ± 0.02 | 0.024 ± 0.005 | 0.014 ± 0.003 |
| Muscle | 0.39 ± 0.24 | 0.06 ± 0.01 | 0.031 ± 0.011 | 0.021 ± 0.005 |
| Lung | 1.35 ± 1.52 | 0.20 ± 0.05 | 0.062 ± 0.006 | 0.040 ± 0.003 |
| Kidney | 1.21 ± 0.94 | 1.48 ± 0.60 | 0.686 ± 0.191 | 0.411 ± 0.125 |
| Spleen | 0.15 ± 0.04 | 0.07 ± 0.01 | 0.038 ± 0.005 | 0.034 ± 0.005 |
| Pancreas | 0.15 ± 0.03 | 0.07 ± 0.02 | 0.021 ± 0.001 | 0.013 ± 0.005 |
| Liver | 0.20 ± 0.03 | 0.13 ± 0.03 | 0.088 ± 0.021 | 0.068 ± 0.013 |
| Skin | 0.41 ± 0.12 | 0.11 ± 0.03 | 0.052 ± 0.006 | 0.042 ± 0.008 |
| Brain | 0.03 ± 0.01 | 0.01 ± 0.00 | 0.003 ± 0.003 | 0.014 ± 0.016 |
| **Bone** | **12.4 ± 1.19** | **11.4 ± 0.31** | **12.7 ± 0.90** | **11.6 ± 1.14** |
| **l.** Radiotracers: [$^{68}$Ga]2 | | | | |
| | 2 min | 30 min | 60 min | 120 min |
| Blood | 9.97 ± 1.40 | 0.73 ± 0.28 | 0.47 ± 0.08 | 0.31 ± 0.09 |
| Heart | 4.13 ± 0.30 | 0.99 ± 0.13 | 0.57 ± 0.13 | 0.42 ± 0.08 |
| Muscle | 2.26 ± 0.34 | 0.32 ± 0.05 | 0.24 ± 0.04 | 0.23 ± 0.05 |
| Lung | 5.47 ± 0.57 | 0.96 ± 0.23 | 0.58 ± 0.09 | 0.40 ± 0.05 |
| Kidney | 19.4 ± 1.38 | 2.98 ± 1.13 | 2.61 ± 0.95 | 2.86 ± 1.16 |
| Spleen | 2.08 ± 0.22 | 0.48 ± 0.09 | 0.43 ± 0.05 | 0.43 ± 0.24 |
| Pancreas | 2.05 ± 0.23 | 0.36 ± 0.17 | 0.27 ± 0.01 | 0.31 ± 0.11 |
| Liver | 2.67 ± 0.12 | 0.44 ± 0.09 | 0.43 ± 0.03 | 0.40 ± 0.03 |
| Skin | 3.19 ± 0.45 | 0.71 ± 0.13 | 0.38 ± 0.05 | 0.33 ± 0.06 |
| Brain | 0.30 ± 0.02 | 0.03 ±0.00 | 0.02 ± 0.00 | 0.02 ± 0.00 |
| **Bone** | **11.0 ±1.95** | **18.8 ± 2.82** | **19.7 ± 4.17** | **23.9 ± 5.54** |
| **m.** Radiotracers: [$^{68}$Ga]3 | | | | |
| | 2 min | 30 min | 60 min | 120 min |
| Blood | 8.33 ± 0.23 | 1.92 ± 0.15 | 0.70 ± 0.13 | 0.37 ± 0.07 |
| Heart | 3.45 ± 0.25 | 2.02 ± 0.97 | 1.16 ± 0.13 | 1.05 ± 0.11 |

| **m.** Radiotracers: [$^{68}$Ga]3 | | | | |
|---|---|---|---|---|
| | 2 min | 30 min | 60 min | 120 min |
| Muscle | 1.62 ± 0.47 | 0.68 ± 0.09 | 0.57 ± 0.14 | 0.28 ± 0.04 |
| Lung | 71.6 ± 6.33 | 15.6 ± 1.39 | 41.3 ± 5.15 | 34.8 ± 1.90 |
| Kidney | 12.2 ± 1.51 | 17.1 ± 0.70 | 7.99 ± 1.08 | 8.99 ± 0.20 |
| Spleen | 12.8 ± 4.35 | 8.33 ± 2.22 | 10.3 ± 2.65 | 15.7± 1.59 |
| Pancreas | 1.73 ± 0.08 | 1.07 ± 1.04 | 0.26 ± 0.02 | 0.25 ± 0.03 |
| Liver | 19.7 ± 1.05 | 9.86 ± 0.66 | 23.5 ± 3.13 | 25.4 ± 2.80 |
| Skin | 1.24 ± 0.01 | 1.10 ± 0.18 | 0.41 ± 0.02 | 0.33 ± 0.06 |
| Brain | 0.28 ± 0.03 | 0.06 ± 0.01 | 0.06 ± 0.01 | 0.05 ± 0.01 |
| **Bone** | **4.17 ± 0.35** | **9.26 ± 1.45** | **9.26 ± 1.13** | **10.6 ± 0.85** |
| **n.** Radiotracers: [$^{68}$Ga]HBED-CC | | | | |
| | 2 min | 30 min | 60 min | 120 min |
| Blood | 7.66 ± 0.75 | 0.83 ± 0.09 | 0.14 ± 0.04 | 0.01 ± 0.00 |
| Heart | 2.74 ± 0.34 | 0.34 ± 0.06 | 0.17 ± 0.11 | 0.09 ± 0.00 |
| Muscle | 2.30 ± 0.13 | 0.32 ± 0.06 | 0.11 ± 0.04 | 0.05 ± 0.02 |
| Lung | 4.27 ± 0.34 | 0.58 ± 0.07 | 0.19 ± 0.04 | 0.07 ± 0.02 |
| Kidney | 27.2 ± 0.64 | 3.22 ± 0.41 | 0.91 ± 0.32 | 0.08 ± 0.05 |
| Spleen | 1.69 ± 0.18 | 0.26 ± 0.04 | 0.12 ± 0.02 | 0.13 ± 0.03 |
| Pancreas | 1.60 ± 0.12 | 0.26 ± 0.01 | 0.13 ± 0.05 | 0.07 ± 0.01 |
| Liver | 1.75 ± 0.08 | 0.38 ± 0.08 | 0.11 ± 0.02 | 0.04 ± 0.02 |
| Skin | 3.18 ± 0.43 | 0.64 ± 0.08 | 0.09 ± 0.07 | 0.03 ± 0.01 |
| Brain | 0.29 ± 0.08 | 0.04 ± 0.01 | 0.02 ± 0.01 | 0.02 ± 0.00 |
| **Bone** | **1.85 ± 0.05** | **0.28 ± 0.06** | **0.25 ± 0.16** | **0.18 ± 0.06** |

**Table 5.** Comparison of a) bone to blood ratio and b) bone to muscle ratio in normal CD-1 male mice after an iv injection

| a) bone to blood ratio | | | | |
|---|---|---|---|---|
| | 2 min | 30 min | 60 min | 120 min |
| [$^{18}$F]NaF | 1.9 | 38 | 161 | 760 |
| [$^{68}$Ga]BPAMD | 0.8 | 10 | 10 | 11 |
| [$^{68}$Ga]1a | 0.9 | 36 | 118 | 320 |
| [$^{68}$Ga]1b | 0.9 | 20 | 50 | 82 |
| [$^{68}$Ga]1c | 0.7 | 8 | 23 | 39 |
| [$^{68}$Ga]1d | 1.1 | 29 | 144 | 278 |

| a) bone to blood ratio | | | | |
|---|---|---|---|---|
| | 2 min | 30 min | 60 min | 120 min |
| [$^{68}$Ga]1e | 1 | 29 | 138 | 230 |
| [$^{68}$Ga]1f | 1 | 33 | 78 | 180 |
| [$^{68}$Ga]1g | 0.97 | 29 | 53 | 98 |
| [$^{68}$Ga]1h | 0.9 | 27 | 112 | 305 |
| [$^{177}$Lu]1h | | 24 | 97 | 909[a] |
| | | | | 4312[b] |
| [$^{68}$Ga]2 | 1.1 | 26 | 42 | 77 |
| [$^{68}$Ga]3 | 0.5 | 4.8 | 13 | 29 |
| b) bone to muscle ratio | | | | |
| [$^{68}$Ga]HBED-CC | 0.2 | 0.3 | 1.7 | 12 |
| | 2 min | 30 min | 60 min | 120 min |
| [$^{18}$F]NaF | 7.2 | 73 | 281 | 593 |
| [$^{68}$Ga]BPAMD | 4.3 | 19 | 30 | 33 |
| [$^{68}$Ga]1a | 4.8 | 96 | 291 | 447 |
| [$^{68}$Ga]1b | 4.7 | 68 | 147 | 197 |
| [$^{68}$Ga]1c | 5 | 49 | 102 | 103 |
| [$^{68}$Ga]1d | 5.9 | 64 | 235 | 417 |
| [$^{68}$Ga]1e | 5 | 67 | 258 | 411 |
| [$^{68}$Ga]1f | 4 | 74 | 222 | 374 |
| [$^{68}$Ga]1g | 3.71 | 46 | 74 | 98 |
| [$^{68}$Ga]1h | 4.3 | 85 | 233 | 383 |
| [$^{177}$Lu]1h | | 41 | 200 | 454[a] |
| | | | | 572[b] |
| [$^{68}$Ga]2 | 4.9 | 58 | 83 | 103 |
| [$^{68}$Ga]3 | 2.6 | 14 | 16 | 39 |
| [$^{68}$Ga]HBED-CC | 0.8 | 0.9 | 2.3 | 3.3 |
| [a]; 6 hr post-inj ection, [b]; 24 hr post-injection | | | | |

**Theranostic agent, 1h: [$^{68}$Ga]1h and [$^{177}$Lu]1h**

**[0077] 1h,** a derivative containing DOTA chelating group for other therapeutic metals, such as $^{177}$Lu and $^{90}$Y, was also prepared as radionuclide therapeutic agents for bone metastasis. The results of a biodistribution study displayed in Table 4j-k showed that the bone uptake for [$^{68}$Ga]**1h** and [$^{177}$Lu]**1h** at 60 min post iv injection in normal mice was 11.9 ± 1.3 and 11.4 ± 0.3 (% dose/g), respectively. The bone to muscle ratio in normal mice for [$^{68}$Ga]**1h** and [$^{177}$Lu]**1h** at 60 min post iv injection was 233 and 200, respectively. The bone to blood ratio in normal mice for [$^{68}$Ga]**1h** and [$^{177}$Lu]**1h** at 60 min post iv injection was 112 and 97, respectively. Both radiotracers also displayed high hydroxyapatite binding (>90%). It is demonstrated that [$^{177}$Lu]**1h** exhibited excellent bone uptake, retention in bone and fast kidney excretion. No differences were observed between [$^{68}$Ga]**1h** and [$^{177}$Lu]**1h.** The DOTA containing agent, **1h** can be employed as a theranostic agent for bone imaging with $^{68}$Ga labeling and for the palliation of metastatic bone pain when it is labeled with $^{177}$Lu or $^{90}$Y.

**In vitro binding studies using hydroxyapatite**

**[0078]** To confirm the binding of [$^{68}$Ga]BPAMD, [$^{68}$Ga]**1a-h, 2,** and **3,** as well as [$^{18}$F]NaF (a positive control), associated with active bone surfaces, these compounds were tested in a modeling system using hydroxyapatite aggregates. An in vitro binding study using the preformed hydroxyapatite aggregates showed that the bisphosphonates, [$^{68}$Ga]BPAMD, [$^{68}$Ga]**1a-h**, **2,** and **3,** as well as [$^{18}$F]NaF, displayed excellent binding in vitro (70-90 % binding) as seen in Table 6. As expected, [$^{68}$Ga]HBED-CC, a chelator without bisphosphonate groups, showed very low hydroxyapatite aggregate binding in vitro (0.4 ± 0.1% binding).

**Table 6.** In vitro hydroxyapatite binding

| Radioligand | Hydroxyapatite Binding (%) |
|---|---|
| [$^{18}$F]NaF | 78.4 ± 3.9 |
| [$^{68}$Ga]BPAMD | 90.6 ± 6.0 |
| [$^{68}$Ga]1a | 92.3 ± 1.1 |
| [$^{68}$Ga]1b | 91.7 ± 5.6 |
| [$^{68}$Ga]1c | 89.1 ± 1.0 |
| [$^{68}$Ga]1d | 95.1 ± 0.5 |
| [$^{68}$Ga]1e | 95.8 ± 0.9 |
| [$^{68}$Ga]1f | 96.4 ± 1.2 |
| [$^{68}$Ga]1g | 88.0 ± 10.5 |

| Radioligand | Hydroxyapatite Binding (%) |
|---|---|
| [$^{68}$Ga]1h | 96.7 ± 0.9 |
| [$^{177}$Lu]1h | 90.9 ± 1.1 |
| [$^{68}$Ga]2 | 90.8 ± 1.5 |
| [$^{68}$Ga]3 | 95.8 ± 0.1 |
| [$^{68}$Ga]HBED-CC | 0.4 ± 0.1 |
| Each value represents the mean ± SD for n=2-4 in triplicates. | |

**Micro-PET imaging of mice for bone**

**[0079]** Micro-PET imaging studies in mice were successfully performed using [$^{18}$F]NaF (0.3 mCi), [$^{68}$Ga]BPAMD (0.5mCi), and [$^{68}$Ga]**1a** (0.5 mCi). Images acquisition was performed for 15 min at 60 min post-injection. The results clearly indicate that all agents localized in the spines of mice as seen in Figures 1-3. Although it is likely that due to the size of mice, the individual sections of vertebrate were not visually separable, the bone uptake of the $^{68}$Ga labeled bisphosphonates and [$^{18}$F]NaF provided equally high bone uptake. The new bone imaging agent, [$^{68}$Ga]**1a,** will likely be suitable as a bone imaging agent, producing comparable images to those previously reported from [$^{18}$F]NaF (Fig 1-3).

**[0080]** Both HBED-CC-BP agents, [$^{68}$Ga]**1a** and [$^{68}$Ga]**2** showed excellent bone uptake and retention comparable to that of [$^{18}$F]NaF. Similar to that of [$^{18}$F]NaF, mechanisms of uptake and retention of these new $^{68}$Ga labeled bisphosphonates are likely associated with the deposition of bisphosphonates via ion exchange reaction on the active bone surfaces (hydroxyapatite). Clearance rates of bone imaging agents from the kidney via glomerular filtration will determine the background clearance, thus strongly influence the signal to noise ratio. It is reported earlier that the fluoride ion showed a high rate of clearance and less reuptake in the kidney, therefore [$^{18}$F]NaF displayed the best bone vs. background ratio in vivo. The new [$^{68}$Ga]HBED bisphosphonate, [$^{68}$Ga]**1a-h** and [$^{68}$Ga]**2**, probably share the same in vivo kinetics of mechanisms for bone uptake and retention. Adding additional amino acid, 2-glucoamine, Glu-NH-CO-NH-Lys(Ahx) or DOTA functional group, **1b-h,** did not significantly changed in vivo kinetics of mechanisms for bone uptake and retention in normal mice.

**[0081]** To test the selective binding of [$^{68}$Ga]**1g** to bone (by bisphosphonate group) and PSMA (by Glu-NH-CO-NH-Lys(Ahx) group) receptor, in vivo biodistribution in mice showed high bone uptakes similar to that of [$^{68}$Ga]**1a** and [$^{68}$Ga]**2** (Table 4). In addition, [$^{68}$Ga]**1g** exhibited high kidney uptake and retention, as kidney is also an organ express high levels of PSMA receptors

(Table 4-i). The biodistribution data in mice support the notion that [$^{68}$Ga]**1g** targets both bone and PSMA binding sites. In vitro binding studies were also performed using PSMA positive LNCaP cells and the PSMA negative PC3 cells. It was observed that [$^{68}$Ga]**1g** exhibited high cell uptake and retention only in LNCaP cells over expressing PSMA binding sites, suggesting that [$^{68}$Ga]**1g** binding to these cells was selective to the PSMA receptors on the membrane of cells (Figure 4 and 5).

**Micro-PET imaging of [$^{68}$Ga]1g in PSMA expressing tumor bearing mouse**

**[0082]** The novel probe, [$^{68}$Ga]**1g**, was invented to target both bone metastasis and actively growing tumor which over-express PSMA. The microPET image in mouse support the notion that [$^{68}$Ga]**1g** targets both bone and PSMA binding sites as shown in Fig 6.

**References**

**[0083]**


1. [1] Iagaru A, Young P, Mittra E, Dick DW, Herfkens R, and Gambhir SS. Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases. Clin. Nucl. Med. 2013;38:e290-6.
2. [2] Jadvar H, Desai B, and Conti PS. Sodium 18F-fluoride PET/CT of bone, joint, and other disorders. Semin. Nucl. Med. 2015;45:58-65.
3. [3] Velikyan I. Continued rapid growth in 68Ga applications: update 2013 to June 2014. J. Label. Compd. Radiopharm. 2015:In Press.
4. [4] Rosch F. Past, present and future of 68Ge/68Ga generators. Appl. Radiat. Isot. 2013;76:24-30.
5. [5] Sanchez-Crespo A. Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Appl. Radiat. Isot. 2013;76:55-62.
6. [6] Velikyan I. Prospective of (68)Ga-radiopharmaceutical development. Theranostics 2013;4:47-80.
7. [7] Velikyan I. The diversity of (68)Ga-based imaging agents. Recent Results Cancer Res. 2013;194:101-31.
8. [8] Price EW and Orvig C. Matching chelators to radiometals for radiopharmaceuticals. Chem. Soc. Rev. 2014;43:260-90.
9. [9] Smith DL, Breeman WA, and Sims-Mourtada J. The untapped potential of Gallium 68-PET: the next wave of (6)(8)Ga-agents. Appl. Radiat. Isot. 2013;76:14-23.
10. [10] Nedrow JR, White AG, Modi J, Nguyen K, Chang AJ, and Anderson CJ. Positron emission tomographic imaging of copper 64- and gallium 68-labeled chelator conjugates of the somatostatin agonist tyr3-octreotate. Mol. Imaging 2014;13:1-13.
11. [11] Banerjee SR and Pomper MG. Clinical applications of Gallium-68. Appl. Radiat. Isot.

2013;76:2-13.

12. [12] Manzoni L, Belvisi L, Arosio D, Bartolomeo MP, Bianchi A, Brioschi C, et al. Synthesis of Gd and (68)Ga complexes in conjugation with a conformationally optimized RGD sequence as potential MRI and PET tumor-imaging probes. ChemMedChem 2012;7:1084-93.
13. [13] Morgat C, Hindie E, Mishra AK, Allard M, and Fernandez P. Gallium-68: chemistry and radiolabeled peptides exploring different oncogenic pathways. Cancer Biother. Radiopharm. 2013;28:85-97.
14. [14] Sandstrom M, Velikyan I, Garske-Roman U, Sorensen J, Eriksson B, Granberg D, et al. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. J. Nucl. Med. 2013;54:1755-9.
15. [15] Velikyan I, Sundin A, Sorensen J, Lubberink M, Sandstrom M, Garske-Roman U, et al. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J. Nucl. Med. 2014;55:204-10.
16. [16] Stasiuk GJ and Long NJ. The ubiquitous DOTA and its derivatives: the impact of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid on biomedical imaging. Chem. Commun. (Camb.) 2013;49:2732-46.
17. [17] De Leon-Rodriguez LM and Kovacs Z. The synthesis and chelation chemistry of DOTA-peptide conjugates. Bioconjug. Chem. 2008;19:391-402.
18. [18] Chappell LL, Ma D, Milenic DE, Garmestani K, Venditto V, Beitzel MP, et al. Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid for radiolabeling proteins. Nucl. Med. Biol. 2003;30:581-95.
19. [19] Mjos KD and Orvig C. Metallodrugs in medicinal inorganic chemistry. Chem. Rev. 2014; 114:4540-63.
20. [20] Holub J, Meckel M, Kubicek V, Rosch F, and Hermann P. Gallium(III) complexes of NOTA-bis (phosphonate) conjugates as PET radiotracers for bone imaging. Contrast Media Mol. Imaging 2015;10:122-34.
21. [21] Meckel M, Fellner M, Thieme N, Bergmann R, Kubicek V, and Rosch F. In vivo comparison of DOTA based 68Ga-labelled bisphosphonates for bone imaging in non-tumour models. Nucl. Med. Biol. 2013;40:823-30.
22. [22] Velikyan I, Maecke H, and Langstrom B. Convenient Preparation of (68)Ga-Based PET-Radiopharmaceuticals at Room Temperature. Bioconjugate Chem. 2008;19:569-73.
23. [23] Eisenwiener KP, Prata MI, Buschmann I, Zhang HW, Santos AC, Wenger S, et al. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug. Chem. 2002;13:530-41.
24. [24] Pohle K, Notni J, Bussemer J, Kessler H, Schwaiger M, and Beer AJ. 68Ga-NODAGA-RGD is a suitable substitute for (18)F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl. Med. Biol. 2012;39:777-84.
25. [25] Oxboel J, Brandt-Larsen M, Schjoeth-Eskesen C, Myschetzky R, El-Ali HH, Madsen J, et al. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human

xenograft tumors. Nucl. Med. Biol. 2014;41:259-67.

26. [26] Fani M, Tamma ML, Nicolas GP, Lasri E, Medina C, Raynal I, et al. In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates. Mol. Pharm. 2012;9:1136-45.
27. [27] Velikyan I, Maecke H, and Langstrom B. Convenient preparation of 68Ga-based PET-radiopharmaceuticals at room temperature. Bioconjug. Chem. 2008;19:569-73.
28. [28] Knetsch PA, Petrik M, Griessinger CM, Rangger C, Fani M, Kesenheimer C, et al. [68Ga]NODAGA-RGD for imaging alphavbeta3 integrin expression. Eur. J. Nucl. Med. Mol. Imaging 2011;38:1303-12.
29. [29] Ogawa K, Takai K, Kanbara H, Kiwada T, Kitamura Y, Shiba K, et al. Preparation and evaluation of a radiogallium complex-conjugated bisphosphonate as a bone scintigraphy agent. Nucl. Med. Biol. 2011;38:631-6.
30. [30] Fellner M, Baum RP, Kubicek V, Hermann P, Lukes I, Prasad V, et al. PET/CT imaging of osteoblastic bone metastases with (68)Ga-bisphosphonates: first human study. Eur. J. Nucl. Med. Mol. Imaging 2010;37:834.
31. [31] Suzuki K, Satake M, Suwada J, Oshikiri S, Ashino H, Dozono H, et al. Synthesis and evaluation of a novel 68Ga-chelate-conjugated bisphosphonate as a bone-seeking agent for PET imaging. Nucl. Med. Biol. 2011;38:1011-8.
32. [32] Fellner M, Biesalski B, Bausbacher N, Kubicek V, Hermann P, Rosch F, et al. (68)Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter. Nucl. Med. Biol. 2012;39:993-9.
33. [33] Toegel S, Wadsak W, Mien LK, Viernstein H, Kluger R, Eidherr H, et al. Preparation and pre-vivo evaluation of no-carrier-added, carrier-added and cross-complexed [(68)Ga]-EDTMP formulations. Eur. J. Pharm. Biopharm. 2008;68:406-12.
34. [34] Seemann J, Eppard E, Waldron BP, Ross TL, and Roesch F. Cation exchange-based post-processing of (68)Ga-eluate: a comparison of three solvent systems for labelling of DOTATOC, NO2AP(BP) and DATA(m.). Appl. Radiat. Isot. 2015;98:54-9.
35. [35] Notni J, Simecek J, and Wester HJ. Phosphinic acid functionalized polyazacycloalkane chelators for radiodiagnostics and radiotherapeutics: unique characteristics and applications. ChemMedChem 2014;9:1107-15.
36. [36] Simecek J, Notni J, Kapp TG, Kessler H, and Wester HJ. Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68)Ga-NOPO-c(RGDfK). Mol. Pharm. 2014;11:1687-95.
37. [37] Simecek J, Zemek O, Hermann P, Notni J, and Wester HJ. Tailored Gallium(III) Chelator NOPO: Synthesis, Characterization, Bioconjugation, and Application in Preclinical Ga-68-PET Imaging. Mol. Pharm. 2013.
38. [38] Huang SS, Wang X, Zhang Y, Doke A, DiFilippo FP, and Heston WD. Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker. Prostate 2014;74:702-13.
39. [39] Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Green G, Fox JJ, et al. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J. Med. Chem. 2010;53:5333-41.
40. [40] Simecek J, Hermann P, Havlickova J, Herdtweck E, Kapp TG, Engelbogen N, et al. A cyclen-based tetraphosphinate chelator for the preparation of radiolabeled tetrameric

bioconjugates. Chemistry 2013;19:7748-57.

41. [41] Simecek J, Hermann P, Wester HJ, and Notni J. How is (68)Ga labeling of macrocyclic chelators influenced by metal ion contaminants in (68)Ge/(68)Ga generator eluates? ChemMedChem 2013;8:95-103.
42. [42] Ramogida CF, Cawthray JF, Boros E, Ferreira CL, Patrick BO, Adam MJ, et al. H2CHXdedpa and H4CHXoctapa-Chiral Acyclic Chelating Ligands for (67/68)Ga and (111)In Radiopharmaceuticals. Inorg. Chem. 2015;54:2017-31.
43. [43] Baur B, Solbach C, Andreolli E, Winter G, Machulla HJ, and Reske SN. Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A"-DTPA-DUPA-Pep. Pharmaceuticals (Basel) 2014;7:517-29.
44. [44] Davis MI, Bennett MJ, Thomas LM, and Bjorkman PJ. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc. Natl. Acad. Sci. U. S. A. 2005;102:5981-6.
45. [45] Jadvar H. Molecular imaging of prostate cancer with PET. J. Nucl. Med. 2013;54:1685-8.
46. [46] Akhtar NH, Pail O, Saran A, Tyrell L, and Tagawa ST. Prostate-Specific Membrane Antigen-Based Therapeutics. Advances in Urology 2012;2012:9.
47. [47] Ristau BT, O'Keefe DS, and Bacich DJ. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol Oncol 2014;32:272-9.
48. [48] Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, and Tagawa ST. Prostate-specific membrane antigen-based imaging. Urol Oncol 2013;31:144-54.
49. [49] Schafer M, Bauder-Wust U, Leotta K, Zoller F, Mier W, Haberkorn U, et al. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res 2012;2:23.
50. [50] Eder M, Neels O, Muller M, Bauder-Wust U, Remde Y, Schafer M, et al. Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. Pharmaceuticals (Basel) 2014;7:779-96.
51. [51] Eder M, Schafer M, Bauder-Wust U, Hull WE, Wangler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug. Chem. 2012;23:688-97.
52. [52] Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2014:Ahead of Print.
53. [53] Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, et al. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur. J. Nucl. Med. Mol. Imaging 2014;41:887-97.
54. [54] Maurer T, Beer AJ, Wester HJ, Kubler H, Schwaiger M, and Eiber M. Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging? Int. J. Urol. 2014;21:1286-8.

55. [55] Chakraborty PS, Tripathi M, Agarwal KK, Kumar R, Vijay MK, and Bal C. Metastatic Poorly Differentiated Prostatic Carcinoma With Neuroendocrine Differentiation: Negative on 68Ga-PSMA PET/CT. Clin. Nucl. Med. 2015;40:e163-6.
56. [56] Eiber M, Nekolla SG, Maurer T, Weirich G, Wester HJ, and Schwaiger M. Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer. Abdom. Imaging 2014.
57. [57] Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2015;42: 197-209.
58. [58] Maurer T, Weirich G, Schottelius M, Weineisen M, Frisch B, Okur A, et al. Prostate-specific Membrane Antigen-radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer. Eur. Urol. 2015.
59. [59] Malik N, Baur B, Winter G, Reske SN, Beer AJ, and Solbach C. Radiofluorination of PSMA-HBED via A1F Chelation and Biological Evaluations In Vitro. Mol. Imaging Biol. 2015.
60. [60] Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J. Nucl. Med. 2015;56:668-74.
61. [61] Clarke ET and Martell AE. 19. Stabilities of trivalent metal ion complexes of the tetraacetate derivatives of 12-, 13- and 14-membered tetraazamacrocycles. Inorg. Chim. Acta 1991;190:37-46.
62. [62] Broan CJ, Cox JPL, Craig AS, Kataky R, Parker D, Harrison A, et al. Structure and solution stability of indium and gallium complexes of 1,4,7,-triazacyclononanetriacetate and yttrium complexes of 1,4,7,10-tetraazacyclododecanetetraacetate and related ligands: kinetically stable complexes for use in imaging and radioimmunotherapy. X-ray molecular structure of the indium and gallium complexes of 1,4,7,-triazacyclononane-1,4,7-triacetic acid J. Chem. Soc., Perkin Trans. 1991;21:87-99.
63. [63] Motekaitis RJ, Rogers BE, Reichert DE, Martell AE, and Welch MJ. Stability and Structure of Activated Macrocycles. Ligands with Biological Applications. Inorg. Chem. 1996;35:3821-7.
64. [64] Sun Y, Anderson CJ, Pajeau TS, Reichert DE, Hancock RD, Motekaitis RJ, et al. Indium (III) and gallium (III) complexes of bis(aminoethanethiol) ligands with different denticities: stabilities, molecular modeling, and in vivo behavior. J. Med. Chem. 1996;39:458-70.
65. [65] Huigen YM, Tji TG, Gelsema WJ, and de Ligny CL. The binding of 99mTc(Sn)-MDP complexes to human serum albumin and other blood proteins determined with gel chromatography and ultrafiltration. Int. J. Rad. Appl. Instrum. [A] 1989;40:629-35.

# REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

**Non-patent literature cited in the description**


- **IAGARU A et al.**Clin. Nucl. Med., 2013, vol. 38, e290-6 [0001]
- **JADVAR H et al.**Semin. Nucl. Med., 2015, vol. 45, 58-65 [0001]
- **VELIKYAN I.**J. Label. Compd. Radiopharm., 2015, [0002]
- **MORGAT C. et al.**Gallium-68: chemistry and radiolabeled peptides exploring different oncogenic pathwaysCancer Biother. Radiopharm., 2013, vol. 28, 85-97 [0004]
- **SANDSTROM M et al.**J. Nucl. Med., 2013, vol. 54, 1755-9 [0004]
- **VELIKYAN I et al.**Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantificationJ. Nucl. Med., 2014, vol. 55, 204-10 [0004]
- **PRICE E.W.ORVIG C.**Chem. Soc. Rev., 2014, vol. 43, 260-90 [0005]
- **OXBOEL J. et al.**Nucl. Med. Biol., 2014, vol. 41, 259-67 [0005]
- **FELLNER M. et al.**Eur. J. Nucl. Med. Mol. Imaging, 2010, vol. 37, 834- [0005]
- **SIMECEK J. et al.**Chem. Med. Chem., 2013, vol. 8, 95-103 [0007]
- **RAMOGIDA C.F. et al.**Inorg. Chem., 2015, vol. 54, 2017-31 [0007]
- **BAUR B. et al.**Pharmaceuticals (Basel), 2014, vol. 7, 517-29 [0007] [0008]
- **SCHAFER M. et al.**EJNMMI Res, 2012, vol. 2, 23- [0008]
- **EDER M. et al.**Pharmaceuticals (Basel), 2014, vol. 7, 779-96 [0008]
- **EDER M. et al.**Bioconjug. Chem., 2012, vol. 23, 688-97 [0008]
- **WUTS, P. G. M.GREENE, T. W.**Greene's Protective Groups in Organic SynthesisJ. Wiley & Sons2007000016-430 [0051]
- **IAGARU AYOUNG PMITTRA EDICK DWHERFKENS RGAMBHIR SS**Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastasesClin. Nucl. Med., 2013, vol. 38, e290-6 [0083]
- **JADVAR HDESAI BCONTI PS**Sodium 18F-fluoride PET/CT of bone, joint, and other disordersSemin. Nucl. Med., 2015, vol. 45, 58-65 [0083]
- Continued rapid growth in 68Ga applications**VELIKYAN I**J. Label. Compd. Radiopharm.In Press20130600 [0083]
- **ROSCH F**Past, present and future of 68Ge/68Ga generatorsAppl. Radiat. Isot., 2013, vol. 76, 24-30 [0083]
- **SANCHEZ-CRESPO A**Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomographyAppl. Radiat. Isot., 2013, vol. 76, 55-62 [0083]
- **VELIKYAN I**Prospective of (68)Ga-radiopharmaceutical developmentTheranostics, 2013, vol. 4, 47-80 [0083]

- **VELIKYAN I**The diversity of (68)Ga-based imaging agentsRecent Results Cancer Res., 2013, vol. 194, 101-31 [0083]
- **PRICE EWORVIG C**Matching chelators to radiometals for radiopharmaceuticalsChem. Soc. Rev., 2014, vol. 43, 260-90 [0083]
- **SMITH DLBREEMAN WASIMS-MOURTADA J**The untapped potential of Gallium 68-PET: the next wave of (6)(8)Ga-agentsAppl. Radiat. Isot., 2013, vol. 76, 14-23 [0083]
- **NEDROW JRWHITE AGMODI JNGUYEN KCHANG AJANDERSON CJ**Positron emission tomographic imaging of copper 64- and gallium 68-labeled chelator conjugates of the somatostatin agonist tyr3-octreotateMol. Imaging, 2014, vol. 13, 1-13 [0083]
- **BANERJEE SRPOMPER MG**Clinical applications of Gallium-68Appl. Radiat. Isot., 2013, vol. 76, 2-13 [0083]
- **MANZONI LBELVISI LAROSIO DBARTOLOMEO MPBIANCHI ABRIOSCHI C et al.**Synthesis of Gd and (68)Ga complexes in conjugation with a conformationally optimized RGD sequence as potential MRI and PET tumor-imaging probesChemMedChem, 2012, vol. 7, 1084-93 [0083]
- **MORGAT CHINDIE EMISHRA AKALLARD MFERNANDEZ P**Gallium-68: chemistry and radiolabeled peptides exploring different oncogenic pathwaysCancer Biother. Radiopharm., 2013, vol. 28, 85-97 [0083]
- **SANDSTROM MVELIKYAN IGARSKE-ROMAN USORENSEN JERIKSSON BGRANBERG D et al.**Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumorsJ. Nucl. Med., 2013, vol. 54, 1755-9 [0083]
- **VELIKYAN ISUNDIN ASORENSEN JLUBBERINK MSANDSTROM MGARSKE-ROMAN U et al.**Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantificationJ. Nucl. Med., 2014, vol. 55, 204-10 [0083]
- **STASIUK GJLONG NJ**The ubiquitous DOTA and its derivatives: the impact of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid on biomedical imagingChem. Commun. (Camb.), 2013, vol. 49, 2732-46 [0083]
- **DE LEON-RODRIGUEZ LMKOVACS Z**The synthesis and chelation chemistry of DOTA-peptide conjugatesBioconjug. Chem., 2008, vol. 19, 391-402 [0083]
- **CHAPPELL LL, MA DMILENIC DEGARMESTANI KVENDITTO VBEITZEL MP et al.**Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid for radiolabeling proteinsNucl. Med. Biol., 2003, vol. 30, 581-95 [0083]
- **MJOS KDORVIG C**Metallodrugs in medicinal inorganic chemistryChem. Rev., 2014, vol. 114, 4540-63 [0083]
- **HOLUB JMECKEL MKUBICEK VROSCH FHERMANN P**Gallium(III) complexes of NOTA-bis (phosphonate) conjugates as PET radiotracers for bone imagingContrast Media Mol. Imaging, 2015, vol. 10, 122-34 [0083]
- **MECKEL MFELLNER MTHIEME NBERGMANN RKUBICEK VROSCH F**In vivo comparison of DOTA based 68Ga-labelled bisphosphonates for bone imaging in non-tumour modelsNucl. Med. Biol., 2013, vol. 40, 823-30 [0083]
- **VELIKYAN IMAECKE HLANGSTROM B**Convenient Preparation of (68)Ga-Based PET-

Radiopharmaceuticals at Room TemperatureBioconjugate Chem., 2008, vol. 19, 569-73 [0083]

- **EISENWIENER KPPRATA MIBUSCHMANN IZHANG HWSANTOS ACWENGER S et al.**NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumorsBioconjug. Chem., 2002, vol. 13, 530-41 [0083]
- **POHLE KNOTNI JBUSSEMER JKESSLER HSCHWAIGER MBEER AJ**68Ga-NODAGA-RGD is a suitable substitute for (18)F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated processNucl. Med. Biol., 2012, vol. 39, 777-84 [0083]
- **OXBOEL JBRANDT-LARSEN MSCHJOETH-ESKESEN CMYSCHETZKY REL-ALI HHMADSEN J et al.**Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumorsNucl. Med. Biol., 2014, vol. 41, 259-67 [0083]
- **FANI MTAMMA MLNICOLAS GPLASRI EMEDINA CRAYNAL I et al.**In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugatesMol. Pharm., 2012, vol. 9, 1136-45 [0083]
- **VELIKYAN IMAECKE HLANGSTROM B**Convenient preparation of 68Ga-based PET-radiopharmaceuticals at room temperatureBioconjug. Chem., 2008, vol. 19, 569-73 [0083]
- **KNETSCH PAPETRIK MGRIESSINGER CMRANGGER CFANI MKESENHEIMER C et al.**68Ga]NODAGA-RGD for imaging alphavbeta3 integrin expressionEur. J. Nucl. Med. Mol. Imaging, 2011, vol. 38, 1303-12 [0083]
- **OGAWA KTAKAI KKANBARA HKIWADA TKITAMURA YSHIBA K et al.**Preparation and evaluation of a radiogallium complex-conjugated bisphosphonate as a bone scintigraphy agentNucl. Med. Biol., 2011, vol. 38, 631-6 [0083]
- **FELLNER MBAUM RPKUBICEK VHERMANN PLUKES IPRASAD V et al.**PET/CT imaging of osteoblastic bone metastases with (68)Ga-bisphosphonates: first human studyEur. J. Nucl. Med. Mol. Imaging, 2010, vol. 37, 834- [0083]
- **SUZUKI KSATAKE MSUWADA JOSHIKIRI SASHINO HDOZONO H et al.**Synthesis and evaluation of a novel 68Ga-chelate-conjugated bisphosphonate as a bone-seeking agent for PET imagingNucl. Med. Biol., 2011, vol. 38, 1011-8 [0083]
- **FELLNER MBIESALSKI BBAUSBACHER NKUBICEK VHERMANN PROSCH F et al.**68)Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitterNucl. Med. Biol., 2012, vol. 39, 993-9 [0083]
- **TOEGEL SWADSAK WMIEN LKVIERNSTEIN HKLUGER REIDHERR H et al.**Preparation and pre-vivo evaluation of no-carrier-added, carrier-added and cross-complexed [(68)Ga]-EDTMP formulationsEur. J. Pharm. Biopharm., 2008, vol. 68, 406-12 [0083]
- **SEEMANN JEPPARD EWALDRON BPROSS TLROESCH F**Cation exchange-based post-processing of (68)Ga-eluate: a comparison of three solvent systems for labelling of DOTATOC, NO2AP(BP) and DATA(m.)Appl. Radiat. Isot., 2015, vol. 98, 54-9 [0083]
- **NOTNI JSIMECEK JWESTER HJ**Phosphinic acid functionalized polyazacycloalkane chelators for radiodiagnostics and radiotherapeutics: unique characteristics and

applicationsChemMedChem, 2014, vol. 9, 1107-15 [0083]

- **SIMECEK JNOTNI JKAPP TGKESSLER HWESTER HJ**Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68)Ga-NOPO-c(RGDfK)Mol. Pharm., 2014, vol. 11, 1687-95 [0083]
- **SIMECEK JZEMEK OHERMANN PNOTNI JWESTER HJT**ailored Gallium(III) Chelator NOPO: Synthesis, Characterization, Bioconjugation, and Application in Preclinical Ga-68-PE**T** ImagingMol. Pharm., 2013, [0083]
- **HUANG SSWANG XZHANG YDOKE ADIFILIPPO FPHESTON WD**Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linkerProstate, 2014, vol. 74, 702-13 [0083]
- **BANERJEE SRPULLAMBHATLA MBYUN YNIMMAGADDA SGREEN GFOX JJ et al.**68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancerJ. Med. Chem., 2010, vol. 53, 5333-41 [0083]
- **SIMECEK JHERMANN PHAVLICKOVA JHERDTWECK EKAPP TGENGELBOGEN N et al.**A cyclen-based tetraphosphinate chelator for the preparation of radiolabeled tetrameric bioconjugatesChemistry, 2013, vol. 19, 7748-57 [0083]
- **SIMECEK JHERMANN PWESTER HJNOTNI J**How is (68)Ga labeling of macrocyclic chelators influenced by metal ion contaminants in (68)Ge/(68)Ga generator eluates? ChemMedChem, 2013, vol. 8, 95-103 [0083]
- **RAMOGIDA CFCAWTHRAY JFBOROS EFERREIRA CLPATRICK BOADAM MJ et al.**H2CHXdedpa and H4CHXoctapa-Chiral Acyclic Chelating Ligands for (67/68)Ga and (111)In RadiopharmaceuticalsInorg. Chem., 2015, vol. 54, 2017-31 [0083]
- **BAUR BSOLBACH CANDREOLLI EWINTER GMACHULLA HJRESKE SN**Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-D**T**PA-DUPA-PepPharmaceuticals (Basel), 2014, vol. 7, 517-29 [0083]
- **DAVIS MIBENNETT MJTHOMAS LMBJORKMAN PJ**Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidaseProc. Natl. Acad. Sci. U. S. A., 2005, vol. 102, 5981-6 [0083]
- **JADVAR H**Molecular imaging of prostate cancer with PE**T**J. Nucl. Med., 2013, vol. 54, 1685-8 [0083]
- **AKHTAR NHPAIL OSARAN ATYRELL LTAGAWA ST**Prostate-Specific Membrane Antigen-Based **T**herapeuticsAdvances in Urology, 2012, vol. 2012, 9- [0083]
- **RISTAU BTO'KEEFE DSBACICH DJT**he prostate-specific membrane antigen: lessons and current clinical implications from 20 years of researchUrol Oncol, 2014, vol. 32, 272-9 [0083]
- **OSBORNE JRAKHTAR NHVALLABHAJOSULA SANAND ADEH KTAGAWA ST**Prostate-specific membrane antigen-based imagingUrol Oncol, 2013, vol. 31, 144-54 [0083]
- **SCHAFER MBAUDER-WUST ULEOTTA KZOLLER FMIER WHABERKORN U et al.**A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PE**T** imaging of prostate cancerEJNMMI Res, 2012, vol. 2, 23- [0083]
- **EDER MNEELS OMULLER MBAUDER-WUST UREMDE YSCHAFER M et al.**Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PE**T**

Tracer for Imaging of Prostate CancerPharmaceuticals (Basel), 2014, vol. 7, 779-96 [0083]

- **EDER MSCHAFER MBAUDER-WUST UHULL WEWANGLER CMIER W et al.**68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imagingBioconjug. Chem., 2012, vol. 23, 688-97 [0083]
- **AFSHAR-OROMIEH AAVTZI EGIESEL FLHOLLAND-LETZ TLINHART HGEDER M et al.**The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancerEur. J. Nucl. Med. Mol. Imaging, 2014, [0083]
- **AFSHAR-OROMIEH AHABERKORN USCHLEMMER HPFENCHEL MEDER MEISENHUT M et al.**Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experienceEur. J. Nucl. Med. Mol. Imaging, 2014, vol. 41, 887-97 [0083]
- **MAURER TBEER AJWESTER HJKUBLER HSCHWAIGER MEIBER M**Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging?Int. J. Urol., 2014, vol. 21, 1286-8 [0083]
- **CHAKRABORTY PSTRIPATHI MAGARWAL KKKUMAR RVIJAY MKBAL C**Metastatic Poorly Differentiated Prostatic Carcinoma With Neuroendocrine Differentiation: Negative on 68Ga-PSMA PET/CTClin. Nucl. Med., 2015, vol. 40, e163-6 [0083]
- **EIBER MNEKOLLA SGMAURER TWEIRICH GWESTER HJSCHWAIGER M**Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancerAbdom. Imaging, 2014, [0083]
- **AFSHAR-OROMIEH AAVTZI EGIESEL FLHOLLAND-LETZ TLINHART HGEDER M et al.**The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancerEur. J. Nucl. Med. Mol. Imaging, 2015, vol. 42, 197-209 [0083]
- **MAURER TWEIRICH GSCHOTTELIUS MWEINEISEN MFRISCH BOKUR A et al.**Prostate-specific Membrane Antigen-radioguided Surgery for Metastatic Lymph Nodes in Prostate CancerEur. Urol., 2015, [0083]
- **MALIK NBAUR BWINTER GRESKE SNBEER AJSOLBACH C**Radiofluorination of PSMA-HBED via A1F Chelation and Biological Evaluations In VitroMol. Imaging Biol., 2015, [0083]
- **EIBER MMAURER TSOUVATZOGLOU MBEER AJRUFFANI AHALLER B et al.**Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical ProstatectomyJ. Nucl. Med., 2015, vol. 56, 668-74 [0083]
- **CLARKE ETMARTELL AE**19. Stabilities of trivalent metal ion complexes of the tetraacetate derivatives of 12-, 13- and 14-membered tetraazamacrocyclesInorg. Chim. Acta, 1991, vol. 190, 37-46 [0083]
- **BROAN CJCOX JPLCRAIG ASKATAKY RPARKER DHARRISON A et al.**Structure and solution stability of indium and gallium complexes of 1,4,7,-triazacyclononanetriacetate and yttrium complexes of 1,4,7,10-tetraazacyclododecanetetraacetate and related ligands: kinetically stable complexes for use in imaging and radioimmunotherapy. X-ray molecular structure of the indium and gallium complexes of 1,4,7,-triazacyclononane-

1,4,7-triacetic acidJ. Chem. Soc., Perkin Trans., 1991, vol. 21, 87-99 [0083]

- **MOTEKAITIS RJROGERS BEREICHERT DEMARTELL AEWELCH MJ**Stability and Structure of Activated Macrocycles. Ligands with Biological ApplicationsInorg. Chem., 1996, vol. 35, 3821-7 [0083]
- **SUN YANDERSON CJPAJEAU TSREICHERT DEHANCOCK RDMOTEKAITIS RJ et al.**Indium (III) and gallium (III) complexes of bis(aminoethanethiol) ligands with different denticities: stabilities, molecular modeling, and in vivo behaviorJ. Med. Chem., 1996, vol. 39, 458-70 [0083]
- **HUIGEN YMTJI TGGELSEMA WJDE LIGNY CLT**he binding of Tc(Sn)-MDP complexes to human serum albumin and other blood proteins determined with gel chromatography and ultrafiltrationInt. J. Rad. Appl. Instrum. [A, 1989, vol. 40, 629-35 [0083]

## Patentkrav

**1.** Forbindelse ifølge formel I:



formel I

eller et farmaceutisk acceptabelt salt deraf,

hvor

A er en divalent forbindelsesenhed omfattende 1 til 10 kulstofatomer i en kæde, en ring eller en kombination deraf, hvor mindst et kulstofatom eventuelt er erstattet med O, -$NR^9$- eller -C(O)-;

B er $CR^3R^4$;

X er udvalgt fra gruppen bestående af:



$X_1$ $X_2$ $X_3$ $X_4$



$X_5$ $X_6$ ;

n er fra 1 til 8;

Y er uafhængigt CH eller N;

$R^1$ er hydrogen eller en ($C_1$-$C_6$) alkylgruppe;

$R^2$, $R^5$ og $R^8$ er uafhængigt hydrogen eller en carboxylsyre-beskyttelsesgruppe;
$R^3$ og $R^4$ er uafhængigt hydrogen, en ($C_1$-$C_{10}$) alkylgruppe, en ethylenglycolylgruppe eller en propylenglycolylgruppe;
$R^6$ er hydrogen eller en ($C_1$-$C_6$) acylgruppe; og
$R^7$ er α-position-substituenten af en aminosyre, og
$R^9$ er uafhængigt udvalgt fra gruppen bestående af H, alkyl, cycloalkyl, heterocycloalkyl, aryl, alkylaryl, arylalkyl og heteroaryl.

**2.** Forbindelse ifølge krav 1, hvor
(i) A er $(CH_2)_m$, hvor m er 0, 1, 2 eller 3;
$R^1$ er Et;
X er udvalgt fra gruppen bestående af:




;

n er fra 1 til 8;
$R^2$, $R^5$, og $R^8$ er t-Bu;
$R^6$ er AcO; og
B, Y, $R^3$, $R^4$, og $R^7$ er defineret som i krav 1.
eller
(ii) A er $CH_2$;
Y er CH;
$R^7$ er udvalgt fra gruppen bestående af hydrogen, methyl, -$CH_2COOR^8$, og

$-(CH_2)_2COOR^8$;
$R^1$, $R^2$, $R^3$, $R^4$, $R^5$, $R^6$ og $R^8$ er hydrogen.

**3.** Forbindelse ifølge krav 1 eller krav 2, hvor
X er

X1 ,

eller
X er



X2

eller



X3 ,

eller
X er



$X_4$ ,

eller
X er



$X_5$ ,

eller

X er



$x_6$ ,

og n er fra 1 til 8.

**4.** Forbindelse ifølge krav 1, som har strukturen:



,



eller



.

**5.** Kompleks omfattende en forbindelse ifølge krav 1, chelateret til et metal M, eller et farmaceutisk acceptabelt salt deraf, hvor M er udvalgt fra gruppen bestående af $^{44}Sc$, $^{47}Sc$, $^{203}Pb$, $^{67}Ga$, $^{68}Ga$, $^{72}As$, $^{111}In$, $^{90}Y$, $^{97}Ru$, $^{62}Cu$, $^{64}Cu$, $^{52}Fe$, $^{52m}Mn$, $^{140}La$, $^{175}Yb$, $^{153}Sm$, $^{166}Ho$, $^{149}Pm$, $^{177}Lu$, $^{142}Pr$, $^{159}Gd$, $^{213}Bi$, $^{67}Cu$, $^{111}Ag$, $^{199}Au$, $^{161}Tb$ og $^{51}Cr$.

**6.** Kompleks ifølge krav 5, som har strukturen ifølge formel II:



II

eller et farmaceutisk acceptabelt salt deraf,

hvor

A er en divalent forbindelsesenhed omfattende 1 til 10 kulstofatomer i en kæde, en ring eller en kombination deraf, hvor mindst et kulstofatom eventuelt er erstattet med O, -$NR^9$- eller -C(O)-;

B er $CR^3R^4$;

X er udvalgt fra gruppen bestående af:



$X_1$ $X_2$ $X_3$ $X_4$



$X_5$ $X_6$ ;

n er fra 1 til 8;

Y er uafhængigt CH eller N;

$R^3$ og $R^4$ er uafhængigt hydrogen, en ($C_1$-$C_{10}$) alkylgruppe, en ethylenglycolylgruppe eller en propylenglycolylgruppe;

$R^5$ og $R^8$ er uafhængigt hydrogen eller en carboxylsyre-beskyttelsesgruppe;

$R^6$ er en ($C_1$-$C_6$) acylgruppe;

$R^7$ er α-position-substituenten af en aminosyre;

$R^9$ er uafhængigt udvalgt fra gruppen bestående af H, alkyl, cycloalkyl, heterocycloalkyl, aryl, alkylaryl, arylalkyl og heteroaryl; og

M er et metal udvalgt fra gruppen bestående af $^{44}Sc$, $^{47}Sc$, $^{203}Pb$, $^{67}Ga$, $^{68}Ga$, $^{72}As$, $^{111}In$, $^{90}Y$, $^{97}Ru$, $^{62}Cu$, $^{64}Cu$, $^{52}Fe$, $^{52m}Mn$, $^{140}La$, $^{175}Yb$, $^{153}Sm$, $^{166}Ho$, $^{149}Pm$, $^{177}Lu$, $^{142}Pr$, $^{159}Gd$, $^{213}Bi$, $^{67}Cu$, $^{111}Ag$, $^{199}Au$, $^{161}Tb$ og $^{51}Cr$;

hvor fortrinsvis

(i) A er $(CH_2)_m$, hvor m er 0, 1, 2 eller 3;

X er udvalgt fra gruppen bestående af:




;

eller

(ii) A er $CH_2$;

Y is CH;

$R^7$ er udvalgt fra gruppen bestående af hydrogen, methyl, $-CH_2COOR^8$ og

$-(CH_2)_2COOR^8$;

$R^3$, $R^4$, $R^5$, $R^6$ og $R^8$ er hydrogen.

**7.** Kompleks ifølge krav 6, hvor

(i) X er



X1 ,

(ii) X er



$X_4$ ,

(iii) X er



$X_5$ ,

eller

(iv) X er



$X_6$ ,

og n er fra 1 til 8.

**8.** Kompleks ifølge krav 5 eller 6, hvor M er $^{68}Ga$.

**9.** Kompleks ifølge krav 6, som har strukturen:



,



,



,

eller



,

hvor n er fra 1 til 8.

**10.** Kompleks ifølge krav 5, som har strukturen:



,

hvor n er fra 1 til 8.

**11.** Farmaceutisk sammensætning omfattende en farmaceutisk acceptabel bærer og forbindelsen eller komplekset ifølge et af kravene 1-10 eller et farmaceutisk acceptabelt salt deraf.

**12.** Fremgangsmåde til in vivo-billeddannelse omfattende indgivelse af en virksom mængde af komplekset ifølge et af kravene 5-10 til et individ og detektering af mønsteret af forbindelsens radioaktivitet i individet.

**13.** Kompleks ifølge et af kravene 5-10 til anvendelse i en fremgangsmåde til in vivo-billeddannelse, hvilken fremgangsmåde omfatter indgivelse af en virksom mængde af komplekset til et

individ og detektering af mønsteret af forbindelsens radioaktivitet i individet.

**14.** Kompleks ifølge krav 5 til anvendelse i en fremgangsmåde til behandling af en eller flere knogletumorer i et individ, hvilken fremgangsmåde omfatter indgivelse af en virksom mængde af komplekset, hvor X er




$X_6$ ,

og n er fra 1 til 8.

**15.** Kit omfattende en steril beholder indeholdende en virksom mængde af forbindelsen ifølge et af kravene 1-4 eller et farmaceutisk acceptabelt salt deraf og instruktioner til terapeutisk anvendelse.

# DRAWINGS




FIG. 1A FIG. 1B FIG. 1C




FIG. 2A FIG. 2B FIG. 2C




FIG. 3A FIG. 3B FIG. 3C




FIG. 4




FIG. 5




FIG. 6A FIG. 6B FIG. 6C




FIG. 6D FIG. 6E FIG. 6F